



Article

SARS-CoV-2 and Its Bacterial Co- or Super-Infections Synergize to Trigger COVID-19 Autoimmune Cardiopathies

Robert Root-Bernstein ^{*}, Jack Huber, Alison Ziehl and Maja Pietrowicz

Department of Physiology, Michigan State University, East Lansing, MI 48824, USA; huberja2@msu.edu (J.H.); ziehlali@msu.edu (A.Z.); pietro10@msu.edu (M.P.)

^{*} Correspondence: rootbern@msu.edu; Tel.: +1-517-884-5039

Abstract: Autoimmune cardiopathies (AC) following COVID-19 and vaccination against SARS-CoV-2 occur at significant rates but are of unknown etiology. This study investigated the possible roles of viral and bacterial mimicry, as well as viral-bacterial co-infections, as possible inducers of COVID-19 AC using proteomic methods and enzyme-linked immunoadsorption assays. BLAST and LALIGN results of this study demonstrate that SARS-CoV-2 shares a significantly greater number of high quality similarities to some cardiac protein compared with other viruses; that bacteria such as *Streptococci*, *Staphylococci* and *Enterococci* also display very significant similarities to cardiac proteins but to a different set than SARS-CoV-2; that the importance of these similarities is largely validated by ELISA experiments demonstrating that polyclonal antibodies against SARS-CoV-2 and COVID-19-associated bacteria recognize cardiac proteins with high affinity; that to account for the range of cardiac proteins targeted by autoantibodies in COVID-19-associated autoimmune myocarditis, both viral and bacterial triggers are probably required; that the targets of the viral and bacterial antibodies are often molecularly complementary antigens such as actin and myosin, laminin and collagen, or creatine kinase and pyruvate kinase, that are known to bind to each other; and that the corresponding viral and bacterial antibodies recognizing these complementary antigens also bind to each other with high affinity as if they have an idiotype-anti-idiotype relationship. These results suggest that AC results from SARS-CoV-2 infections or vaccination complicated by bacterial infections. Vaccination against some of these bacterial infections, such as *Streptococci* and *Haemophilus*, may therefore decrease AC risk, as may the appropriate and timely use of antibiotics among COVID-19 patients and careful screening of vaccinees for signs of infection such as fever, diarrhea, infected wounds, gum disease, etc.

Keywords: COVID-19; SARS-CoV-2; myocarditis; endocarditis; MIS-C; autoimmune; cross-reactive; molecular mimicry; antigenic complementarity; cardiolipin; myosin; laminin; *Streptococci*; *Staphylococci*; *Enterococci*; *Klebsiella*; adenovirus; vaccine



Citation: Root-Bernstein, R.; Huber, J.; Ziehl, A.; Pietrowicz, M. SARS-CoV-2 and Its Bacterial Co- or Super-Infections Synergize to Trigger COVID-19 Autoimmune Cardiopathies. *Int. J. Mol. Sci.* **2023**, *24*, 12177. <https://doi.org/10.3390/ijms241512177>

Academic Editor: Mirela Cleopatra Tomescu

Received: 8 July 2023

Revised: 20 July 2023

Accepted: 26 July 2023

Published: 29 July 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Autoimmune complications sometimes follow infection with SARS-CoV-2, the virus that causes COVID-19 [1–3], or, more rarely, following vaccination against SARS-CoV-2 [4–7]. Myocarditis or pericarditis are the most common autoimmune complications [1–7]. Estimates of the prevalence of myocarditis among COVID-19 patients range from a low of 20–30% of hospitalized patients [8,9] to a high of 50–70% among intensive care unit (ICU) patients and post-recovery COVID-19 patients [9–11] and from a low of 1–2% among mild cases to 10–20% [9,10]. Myocardial injury as measured by increased troponin significantly increased the probability of death among hospitalized COVID-19 patients (51.2% vs. 4.5%; $p < 0.001$), correlated significantly with a diagnosis of acute respiratory distress syndrome (ARDS) (58.5% vs. 14.7%), and predicted the need for invasive or non-invasive respiratory support (46.3% vs. 3.9%) [9,12–14]. Most importantly, from the perspective of autoimmunity, a significant proportion of myocarditis patients have been polymerase chain reaction (PCR) negative but positive for SARS-CoV-2 antibodies, suggesting that their cardiac complications have

followed the resolution of their viral infection [10,12,15–17]. In sum, SARS-CoV-2-infected individuals were 18.28 times more likely to develop myocarditis than uninfected, unvaccinated individuals [18], with hospitalized COVID-19 patients having a 20–60% probability of developing myocarditis and as many as 70% of COVID-19 survivors displaying clinical signs of myocardial damage more than a month after their recovery.

Myocarditis has also been reported rarely among SARS-CoV-2 vaccinees. A study of clinically apparent myocarditis among U.S. military personnel vaccinated with either the BNT162b2-mRNA vaccine (Pfizer-BioNTech) or the mRNA-1273 vaccine (Moderna) found a rate of about 1 in 100,000 vaccinees [19], a rate about 3 times lower than reported to the United States Vaccine Adverse Event Reporting System (VAERS) [20] and much less than the 5/100,000 reported among Israeli military personnel [21]. Other studies suggest an incidence rate as high as 10 to 20 cases per 100,000 subjects [7,22–24]. The majority of cases are among men under the age of 65 [4,6].

The data summarized above poses a number of puzzles. One is why the vast majority of people who contract COVID-19 do not develop autoimmune cardiopathies; however, the incidence of these complications becomes increasingly likely the more serious an individual's COVID-19 disease becomes, so that they affect the majority of intensive care unit patients. Similarly, what explains the much lower incidence of post-vaccinal myocarditis and its increased incidence among young men as compared with other COVID-19 vaccines? In this context, it is important to realize that one of the differences between people getting vaccinated against COVID-19 and those being hospitalized for it or admitted to intensive care is their probability of having a bacterial co-infection. This risk is presumably extremely low among vaccinees, who are likely to be healthy, but has been estimated to be between 30% and 90% among hospitalized COVID-19 patients [25–32]. *Streptococci*, *Staphylococci*, *Klebsiella*, *E. coli*, and *Enterococcus faecium* are the most commonly diagnosed SARS-CoV-2 co- or super-infections [25–32]. These bacteria are, notably, among the bacteria most often associated with triggering endocarditis both prior to and during the COVID-19 pandemic [33–36] and therefore possible triggers for cardiac autoimmunity, and their presence preceding some cases of COVID-19-related autoimmune myocarditis has been documented [37,38]. Myocarditis following COVID-19 vaccination has been suggested to result from accidental intravenous inoculation of the vaccine, which would explain the rarity with which autoimmune complications are observed [39] but not the unusual risk in young men.

The autoantigen targets of autoimmune myocarditis have been well-characterized in human patients and include, but are not limited to, actin, beta-adrenergic, cardiolipin, collagen, receptors, creatine kinase, alpha enolase, laminin, myosin, nuclear antigens, pyruvate kinase, tropomyosin, and troponin [36,40–45]. Autoantibodies against many of these proteins have been documented among hospitalized COVID-19 patients (Table 1) [46–53]. The mechanism by which autoantibodies against these antigens are elicited, however, remains obscure. Among the mechanisms that have been proposed are intermittent virus shedding, viral reactivation, or reinfection with another SARS-CoV-2 strain [54], molecular mimicry between SARS-CoV-2 and cardiac antigens [2], and molecular mimicry enhanced by a bystander infection promoting a hyperinflammatory environment [3]. Direct ACE-2-mediated cardiomyocyte damage by the virus; microvascular disease with vascular leakage and hypercoagulation due to endothelitis; systemic hyperacute inflammatory response syndrome; and pneumonia-related oxygen supply-demand imbalance with ischemia [11]. Oddly, given the significant literature linking myocarditis and rheumatic heart disease to viruses and bacteria that display molecular mimicry to heart proteins [41,55–57], this autoimmune disease mechanism has been proposed [4–7] but not investigated with regard to COVID-19-associated autoimmune cardiopathies, nor has the possibility that bacteria are involved in the pathogenesis of this autoimmunity been explored. The purpose of this paper is to test whether SARS-CoV-2 antibodies mimic cardiac antigens and whether such mimicry is sufficient to explain the risks of autoimmune myocarditis associated with COVID-19 and vaccination against it. The possible role of bacterial co-infections, either as bystander infections or active triggers of autoimmune myocarditis, is also explored.

Table 1. A summary of known percentages of individuals diagnosed with antibodies against human cardiac autoantigens as a function of disease status or health. Numbers in brackets refer to article numbers in the references. Pre-COVID AM refers to autoimmune myocarditis diagnosed in patients prior to the COVID-19 pandemic; Pre-COVID DCM refers to patients diagnosed with dilated cardiomyopathy prior to the COVID-19 pandemic; # = number; Hosp. refers to hospitalized patients; ICU refers to patients admitted to an intensive care unit. The number of patients in some columns varied from row to row because the cited reference is a review aggregating several previous studies. AM = autoimmune myocarditis; DCM = dilated cardiomyopathy; Hosp. = hospitalized (severe); ICU = intensive care unit admitted; ACE2 = angiotensin converting enzyme 2; ANCA = perinuclear anti-neutrophil cytoplasmic antibody; β 2GPI = anti-beta 2 glycoprotein I; β Adrenergic Rec. = beta adrenergic receptors 1 or 2; BPI = bactericidal permeability-inducing protein (vasculitis-associated).

Studies [36–45]	[42] Review	[42] Review & [50]	[46,50,51]	[47,49,51]	[47,48]	[42,48,51]
Antibody Targets in Autoimmune Cardiopathies	Pre-COVID AM	Pre-COVID DCM	Hospitalized COVID-19 Patients	ICU COVID-19 Patients	Out-Patient COVID-19	Healthy Controls
# of Patients Studied	Varied	Varied	147; 104; 118	29; 36; 118	24; 118	30; 36; Varied
Actin		71%				
ACE2			3.8–4.0%	27.2%		0.0%
ANCA				8.3–10.3%	8.3%	
β 2GPI			41.6%	30.9%	4.0%	0.0%
β Adrenergic Rec.		30–75%				12–18%
BPI			23.5%			
Cardiolipin				20.6%	25.0%	3.0%
Collagen						
Enolase						
Laminin	73%	78%				6%
Mitochondria	91%	57%				0.0%
Myosin			7.9%			
Phospholipids			7.9%			
Tropomyosin		55%				
Troponin 1			47.8%			
Cardiac Muscle	59%	28–45%	68%	27.8%	0.0%	0–3.0%
Skeletal Muscle				19.4%	0.0%	
Smooth Muscle				30.6%	16.7%	

2. Results

As a first step in identifying possible triggers of myocardial autoimmunity following SARS-CoV-2 infections, two types of similarity searches were carried out. BLAST was used to identify similarities between human proteins and bacterial or viral proteomes, while LALIGN was used to identify similarities between specific pairs of human proteins and SARS-CoV-2 proteins. Only matches that had a Waterman-Eggert score of at least 50, an E value of less than 1.0, and contained a sequence of ten amino acids in which at least six were identical were counted as sufficiently similar to induce possible cross-reactive immunity; this criterion is based on substantial research demonstrating that sequences

exhibiting at least this degree of similarity have a >85% probability of being cross-reactive under experimental conditions [58–61].

BLAST and LALIGN results of this study demonstrate that SARS-CoV-2 shares a significantly greater number of similarities to some cardiac proteins and that these similarities are of higher quality compared with other viruses; that bacteria such as *Streptococci* and *Staphylococci* also display very significant similarities to cardiac proteins but to a different set than SARS-CoV-2; that these similarities are largely validated by ELISA experiments demonstrating that polyclonal antibodies against SARS-CoV-2 and bacteria that are often found as co- or super-infections in COVID-19 recognize cardiac proteins with high affinity; that to account for the range of cardiac proteins targeted by autoantibodies in COVID-19-associated autoimmune myocarditis, both viral and bacterial triggers are probably required; that the targets of the viral and bacterial antibodies are often molecularly complementary antigens such as actin and myosin that are known to bind to each other; and that the corresponding viral and bacterial antibodies recognizing these complementary antigens also bind to each other with high affinity as if they have an idiotype-anti-idiotype relationship. Each of these results will be presented in a separate section.

2.1. Proteomic Study of Similarities Shared by SARS-CoV-2 and Human Cardiac Proteins

Proteomic studies of virus-cardiac protein similarities were carried out using LALIGN, resulting in pairwise comparisons summarized in Figure 1. This method allowed the potential contribution of each to COVID-19-associated cardiomyopathies to be predicted. A special focus was put on the spike protein of SARS-CoV-2, since that is used in most COVID-19 vaccines and is the most likely trigger for associated post-vaccinal AM. The similarities for all the SARS-CoV-2 proteins were summed for each cardiac protein to obtain the total number of similarities contained in the virus as a whole. Some of the most noteworthy similarities between human cardiac proteins and those of SARS-CoV-2 are provided below in Figure 2 (SARS-CoV-2 spike protein) and Figure 3 (SARS-CoV-2 replicase).

These results show that the spike protein (SP) and replicase proteins exhibit the most and highest quality similarities with human cardiac proteins among the SARS-CoV-2 components. The SP contains multiple sequences that mimic a range of cardiac proteins, including myosin, laminins, collagens, beta-2 adrenergic receptor (B2AR), angiotensin converting enzyme 2 (ACE2), and pyruvate kinase (Figures 1 and 2). SARS-CoV-2 replicase also mimics myosin, collagens, B2AR, ACE2, and pyruvate kinase, as well as actin and creatine kinase (Figures 1 and 3). Many of these similarities are of very high quality, sharing six or seven amino acids in a sequence of ten and exhibiting very high Waterman-Eggert (WE) scores (>60) and/or unusually low E values (significantly less than 1.0). These criteria are based on substantial research demonstrating that sequences exhibiting at least this degree of similarity have a >85% probability of being cross-reactive under experimental conditions [58–61]. The statistical significance of these values will be discussed below. The SARS-CoV-2 nucleoprotein and protein 3a account for most of the additional similarities observed to cardiac proteins, with the remaining SARS-CoV-2 proteins contributing a few high-quality matches.

Two types of information are required to interpret these results and the additional proteomic data that follow this section. First, it is necessary to know the probability that the quality of matches reported here may appear by chance. LALIGN contains several internal measures of such probability, including the Waterman-Eggert (WE) score and the E value. In general, WE scores above 50 and E values below 1.0 are considered statistically significant matches, as determined by the probability that these values will occur in a random search involving proteins of similar sizes against the entire protein database [62]. However, Waterman and Eggert explicitly caution users of LALIGN and BLAST to run their own study-appropriate controls as well [62].

	TOTAL	P0DTD1 Repli- case 1ab	P0DTC2 Spike Protein	P0DTC3 Protein 3a	P0DTC4 Envel- ope	P0DTC5 Memb- rane	P0DTC6 Protein 6	P0DTC7 Protein 7a	P0DTC8 Protein 8	P0DTC9 Nucleo- protein	P0DTD2 Protein 9b	P0DTD3 Protein 14	P0DTD8 Protein 7b
>6 of 10/6 of 10 E>70/E>60<70	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60
P13533 Cardiac myosin	3/11 1/6	1/4 1/5	1/0 0/0	0/1 0/0	0/1 0/0	0/1 0/0	1/1 0/0	0/0 0/0	0/0 0/0	0/1 0/1	0/1 0/0	0/1 0/0	0/0 0/0
P68032 Cardiac actin	1/12 1/1	0/3 0/0	0/4 0/0	1/1 1/1	0/2 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/3 0/0	0/0 0/0	0/0 0/0	0/0 0/0
P02452 Collagen 1 alpha	2/6 0/4	1/1 0/1	1/1 0/1	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/1 0/0	0/1 0/2	0/0 0/0	0/0 0/0	0/0 0/0
P02461 Collagen III	2/9 1/7	2/4 0/2	0/0 0/1	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/3 1/4	0/0 0/0	0/0 0/0	0/0 0/0
P53420 Collagen IV	1/17 1/3	0/6 0/1	0/1 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/2 0/0	1/6 1/2	0/0 0/0	0/0 0/0	0/0 0/0
P25391 Laminin 1	3/27 0/7	0/6 0/2	1/7 0/1	0/3 0/2	0/2 0/0	0/1 0/0	1/1 0/0	0/0 0/0	0/2 0/0	1/3 0/2	0/1 0/0	0/0 0/0	0/1 0/0
Q16363 Laminin 4	4/14 5/14	1/8 3/8	0/3 1/5	1/1 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	1/1 0/0	1/0 1/1	0/0 0/0	0/0 0/0	0/0 0/0
P08588 Beta 1 ADR	0/3 0/0	0/2 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0
P07550 Beta 2 ADR	3/12 1/3	0/6 0/1	1/4 1/0	0/1 0/1	0/0 0/0	0/0 0/1	0/1 0/0	1/0 0/0	0/0 0/0	1/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0
P35348 Alpha 1A ADR	0/8 0/1	0/4 0/1	0/2 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0
P06732 Creatine Kinase M	0/6 0/0	0/3 0/0	0/1 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0
P14618 Pyruvate Kinase M	1/5 0/0	1/5 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0
P78310 CXADR	2/8 0/3	0/3 0/2	0/2 0/0	0/1 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	1/0 0/1	0/1 0/0	0/0 0/0	0/0 0/0	1/0 0/0
Q9BYF1 ACE 2	1/15 1/6	1/4 1/5	0/4 0/1	0/3 0/0	0/0 0/0	0/2 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/1 0/0	0/0 0/0
P02749 β 2GPI	0/5 0/1	0/3 0/1	0/1 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0
P06733 Alpha- enolase	0/10 0/3	0/6 0/2	0/0 0/1	0/1 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/1 0/0
P13805 Troponin	0/2 0/0	0/1 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0
P08174 CD55/DAF	3/6 1/5	3/2 1/3	0/0 0/1	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/1 0/0	0/0 0/0	0/2 0/1	0/0 0/0	0/0 0/0	0/1 0/0
TOTALS	24/178 11/63	6/66 5/30	3/29 2/9	2/12 1/4	0/8 0/0	0/8 0/1	2/7 0/0	1/3 0/0	2/6 0/1	4/17 3/10	0/5 0/0	0/2 0/0	1/2 0/0

Figure 1. Summary of the number of LALIGN matches of SARS-CoV-2 proteins with cardiac proteins satisfying various criteria: TOP NUMBER LEFT in each box is the number of matches with that protein in which there were seven or more identical amino acids in a sequence of ten; TOP NUMBER RIGHT in each box is the number of matches with that protein in which there were six identical amino acids in a sequence of ten; BOTTOM NUMBER LEFT in each box is the number of matches that had an E score of 70 or greater; BOTTOM NUMBER RIGHT in each box is the number of matches that had an E score of 60 or more but less than 70. A number of matches meeting each criterion is summed for each cardiac protein (second column from the left) and for each SARS-CoV-2 protein (bottom row).

A previous study using the same methodology employed here provided one set of study-appropriate controls. In the previous study, the likelihood of 13 polypeptides being similar to any of the 25 peptide receptors (325 comparisons) was calculated. Only 0.3% involved matches with an identity score of 7 out of 10, and only 1.8% achieved 6 out of 10. In contrast, 10.0% of the 216 SARS-CoV-2-cardiac protein comparisons exhibited a 7 out of 10 (or better) match, and 40.3% exhibited a 6 out of 10 match. Correspondingly, while none of the polypeptide-receptor pairings achieved a WE score above 50, 9 of 216 SARS-CoV-2-cardiac protein comparisons (4.1%) achieved WE scores of 70 or above, and 32 of 216 comparisons (14.8%) achieved WE scores between 60 and 70. Formal statistics are not required to observe that the differences between the polypeptide/receptor results and the SARS-CoV-2/cardiac protein results are significantly different. Notably, the majority of the high-quality matches involving SARS-CoV-2 were concentrated in the SP and replicase proteins (Figure 1).

SARS-CoV-2 Spike Protein (P0DTC2) Similarities to Human Cardiac Proteins

Cardiac Actin P68032 vs P0DTC2

WE score: 44; 17:3 bits; E(1) < 0.95

ACTIN DLAGRDL 181-187

||:|:|

SPIKE DIAARDL 843-849

WE score: 44; 17:3 bits; E(1) < 0.95

ACTIN SGDGVTHNV 157-165

:| ||:|

SPIKE NGIGVTQNV 907-915

Cardiac Myosin P13533 vs P0DTC2

WE score: 59; 22:6 bits; E(1) < 0.32

MYOSIN SSFQTVSALHRENL 644-657

: |||: |||: |

SPIKE TRFQTLALHRSYL 236-249

WE score: 52; 20:3 bits; E(1) < 0.84

MYOSIN ATSVQIEMNKKREAEFQKMRDLSEAT1158-84

:| | :| ||| ||: ||: :|

SPIKE GTGVLTESNKKF-LPFQQFGRDIADTT 548-73

WE score: 51; 20:0 bits; E(1) < 0.9

MYOSIN KNLQEEISDLTE 1505-1516

|||:|: ||:|

SPIKE KNLNESLIDLQE 1191-1202

WE score: 45; 18:0 bits; E(1) < 1

MYOSIN VKQLEKEKSEFKELD 1215-1231

| : | : | : || |||

SPIKE VYDPLQPELDSFKELD 1137-1153

Laminin 1 P25391 vs P0DTC2

WE score: 59; 22:1 bits; E(1) < 0.59

LAMA1 LLHAPTGTCDGQAHISLVRNR 2570-2592

|||:| :| | :|:|:|:

SPIKE LLHAPATVC--GPKKSTNLVKNK 517-537

WE score: 57; 21:5 bits; E(1) < 0.74

LAMA1 VLLVLLLCVAAQC 5-17

|:|:| |:|:|

SPIKE VFLVLLPLVSSQC 3-15

WE score: 55; 20:8 bits; E(1) < 0.88

LAMA1 TSCSCSLG 718-726

||| ||| |

SPIKE TSCSCSLG 1238-1246

Collagen 1 P02452 vs P0DTC2

WE score: 61; 22:9 bits; E(1) < 0.21

COLL1 AGFDFS-FLPQP--PQEK 1188-1209

:||:| :|:| |:|:

P0DTC2 GGFNFSQILPDPSKPSKRS 792-816

WE score: 47; 18:3 bits; E(1) < 1

COLL1 ADDANVVRD-RDLEV-DTT 1218-1234

||:|:| ||| :|:| |:

P0DTC2 ADTTDAVRDPQTLEILDIT 570-588

Collagen IV P53420 vs P0DTC2

WE score: 50; 19:9 bits; E(1) < 0.89

COLLIV SPGSCLEDFRAAPFL-ECQGRQG 1618-1639

| :| \: | ||| :|:|

P0DTC2 SANNCTFEYVSQPPFLMDLEGKQG 162-184

B2AR P07550 vs P0DTC2

WE: 78; 25.7 bits; E(1) < 0.0094

(336-367 | 238-267)

B2AR FQELLCLRRSSLKAYNGYSSNGTGEQSGYHV

||:| |:| | | ||:| | :|:|

P0DTC2 FQTLALHRSYLTP---GDSSSGWTAGAAAYV

WE: 55; 19.4 bits; E(1) < 0.53

B2AR KYQSLTLTKNKARVILMY 133-157

| |||:| |:| :|:|

P0DTC2 KTQSLIVNNATNVVIVK 106-130

WE score: 43; 16.1 bits; E(1) < 1

B2AR FGNVLVIT 49-56

|| | |||

P0DTC2 FGGVSVIT 593-600

WE score: 41; 15.6 bits; E(1) < 1

B2AR VDRYFAI-TSP

:|:| |||

P0DTC2 LDKYFKNHTSP

ACE2 Q9BYF1 vs P0DTC2

WE score: 66; 22.5 bits; E(1) < 0.16

ACE2 ANEGFHEAVGEIM-SLSAAT 396-414

||: |:|:|:| |||:|

P0DTC2 ANQ-FNSAIGKIQDSLSTA 924-942

WE score: 54; 19:1 bits; E(1) < 0.84

overlap (2-33|254-280)

ACE2 SSSSWLLSLVAVTAAQSTIEEQAKTFLDKFN

||| | :| :| :| :|:| |:

P0DTC2 SSSGW-----TAGAAAYVGYLQPRTELLKYN

WE score: 51; 18:2 bits; E(1) < 0.96

50:0% identity (56:2% similar) in 16 aa

ACE2 LEFLGIQPTLGPPNQF 722-737

|: | ||| | ||

P0DTC2 LQSYGFQPTNGVGYQP 492-507

Waterman-Eggert score: 45; 16.5 bits;

sp|Q9B VPFQK-KPNI-DVTDAMVD 283(-299

:| | :| |:| | /|

P0DTC2 LPFQQFGRDIADTTDAVRD 560-578

Pyruvate Kinase P14618 vs P0DTC2

PK ITLDNAYME-KCD 142-153

|| ||:| :|:

P0DTC2 ITTDNTFVSGNCD 1115-1127

PK QHLIAREAEAAIYHLQ 378-393

|:|:|:| :|:| :|:

P0DTC2 QKLIANQFNSAIGKIQ 920-935

Figure 2. Examples of LALIGN-derived SARS-CoV-2 spike protein (P0DTC2) similarities to human cardiac proteins. Vertical lines indicate identities between the amino acids; double dots indicate conserved amino acid substitutions. WE stands for Waterman-Eggert score (the larger the score, the less likely the similarity is due to chance). E is a measure of probability inverse to the WE score, so the smaller E, the less likely the match is due to chance. The numbers following the protein name are the UniProtKB identifiers. Numbers following the amino acid sequence (or in parentheses before the sequence) define the place of the match in the amino acid sequences of the protein.

SARS-CoV-2 Replicase 1ab (PODTD1) Similarities to Human Cardiac Proteins

Cardiac actin P68032 vs PODTD1

WE 51; 19.6 bits; E(1) < 0.96
ACTIN ENEMATAASSSSLEKSYEL 226-244
|:| :| :: \|||||
PODTD1 EHEHEIAWYTERSEKSYEL 233-251

WE 49; 19.0 bits; E(1) < 0.99
ACTIN DGQVITIGN 246-254
||:|||| |
PODTD1 DGEVITFDN 1547-1555

WE 44; 17.3 bits; E(1) < 1
ACTIN TLLTEAPLNPK 105-115
||||:| |:
PODTD1 TLLTKGTLEPE 5734-5744

Cardiac Myosin 6 P13533 vs PODTD1

WE 64; 24.0 bits; E(1) < 0.56
(267-299 | 1335-1366)
MYOSIN YLLEKSRVIFQLKAERNYHIFYQILSNKKPELL
| :|:|:|:|:| :| :|:|:| :|:|:| :|:
PODTD1 YTVEEAKTVLK-KCKSAFYILPSIISNEKQEIL

WE 59; 22.6 bits; E(1) < 0.32
MYOSIN SSFQTVSALHREN 644-657
: |||: |||| |
PODTD1 TRFQTLALHRSYL 236-249

WE 56; 21.5 bits; E(1) < 0.99
MYOSIN QIALKGGK 1804-1811
:|||||||
PODTD1 KIALKGGK 2757-2764

WE 54; 20.8 bits; E(1) < 1
MYOSIN KKNMEQFIKDLQHLDE 1785-1801
:| :| :|:|:|:| |
PODTD1 NKIADKYVRNLQHLRYE 5105-5121

WE 53; 20.5 bits; E(1) < 1
MYOSIN SRTLEDQANEYRV 1251-1263
)||||: /|: ||
PODTD1 SRTLETAQNSVRV 549-561

Collagen IV P53420 vs PODTD1

WE 57; 22.4 bits; E(1) < 0.88
COLLIV LGMPRLWTGYSLLYL 1482-1496
|||| ||| |
PODTD1 LGMPSYCTGYREGYL 2257-2271

WE 52; 20.8 bits; E(1) < 1
COLLIV IGDGPKGF 1450-1458
| /| ||||
PODTD1 IDHPNPKGF 4334-4341

Laminin 1 P25391 vs PODTD1

WE 62; 23.1 bits; E(1) < 0.91
LAMA1 IPVETVDSNLSHADVII 595-612
:|:|:|:|:| :| | :|
PODTD1 LPTQTVDSQSGSEYDYVI 5852-5869

WE 59; 22.1 bits; E(1) < 0.59
LAMA1 LLHAPTGTCSGQAHSISLVNR 2570-92
||||: :| | :|:|:|:
PODTD1 LLHAPATVC--GPKKSTNLVKNK 516-537

WE 58; 21.8 bits; E(1) < 1
LAMA1 VLSDIEYILIKAS 1313-1325
|:|:|:|:| :|:|:
PODTD1 VVSDIDYVPLKSA 6384-6397

ACE2 Q9BYF1 vs PODTD1

WE 88; 28.4 bits; E(1) < 0.016
ACE2 SWRSEVGKQLRPLYEEYV 167-184
|| |||| /||/ :||
PODTD1 SW--EVGKPRPPLNRNYV 5490-5505

WE 65; 22.1 bits; E(1) < 0.72
ACE2 IEDVEHTFEEIKPLYEHLHAYV 223-244
:|:|:| :|:|:| | :|:| :|:
PODTD1 VEEVTTTLEETKFLTENLLYI 1236-1257

WE 60; 20.7 bits; E(1) < 0.96
(637-660 | 3185-3212)
ACE2 DNEMYL-FRSSVAYAMROY--FLKVKNQ
:|:|:|:| :|:|:|:| :| | :| :|:
PODTD1 NKEMYLKLRSDVLLPLTQYNRYLALYNK

WE 51; 19.3 bits; E(1) < 1
ACE2 NETEINFLKQALTIVG 432-448
:|:|:|:| | | |||
PODTD1 SDIDITFLKKDAPYIVG 1272-1288

Creatine Kinase P06732 vs PODTD1

CK QKIEEIFKKAGHPFM 258-272
||| ||| :|:|
PODTD1 QKIAEIPKEEVKPF 1201-1215

CK FTVDDVIQTGV 51-61
:| | |:|:|
PODTD1 YIVGDVVQEGV 1285-1295

CK YYPLKSMT 173-180
| |||| |
PODTD1 YVPLKSAT 6390-6397

Pyruvate Kinase P14618 vs PODTD1

PK TLKEMIKSGMN 60-70
:|:|:|:|:|
PODTD1 SLKELLQNGMN 3530-3540

PK ARGFFKKGDVV 499-509
:|:|:|:| :| |
PODTD1 SKGFFKEGSSV 4817-4827

PK AQKMMIGRCNRAGKP 309-323
:| :|| |:|:|:|
PODTD1 SEAFILIG-CNYLGKP 7000-7013

PK DIQDLKFG 225-232
|:|:|:|:|
PODTD1 DLQDLKWA 4187-4194

Figure 3. Examples of LALIGN-derived SARS-CoV-2 replicase protein (PODTD2) similarities to human cardiac proteins. Vertical lines indicate identities between the amino acids; double dots indicate conserved amino acid substitutions. WE stands for Waterman-Eggert score (the larger the score, the less likely the similarity is due to chance). E is a measure of probability inverse to the WE score, so the smaller E, the less likely the match is due to chance. The numbers following the protein name are the UniProtKB identifiers. Numbers following the amino acid sequence (or in parentheses before the sequence) define the place of the match in the amino acid sequences of the protein.

An additional set of internal study controls is provided in Section 2.2.

2.2. Proteomic Study of Similarities Shared by Proteins of Other Viruses and Human Cardiac Proteins

LALIGN was also used to explore the number and quality of similarities between viruses other than SARS-CoV-2 and human cardiac proteins. The viruses chosen as controls included two that have previously been associated with AM and DCM as possible triggers of the autoimmunity–coxsackievirus type B3 (CXB3) [63–66] and adenovirus type 5 (Ad5) [66,67]—and three that have a questionable association with AM and DCM—hepatitis C virus (HCV) and poliovirus (PV)—or no known association: influenza A H1N1 [63,66,68]. The results, summarized in Figure 4, revealed that SARS-CoV-2 has significantly more similarities to heart proteins (Table 2) of higher quality (Table 3) than do any of the other viruses. Tables 2 and 3 also show that the influenza A virus has significantly fewer high-quality matches with cardiac proteins compared with all of the other viruses. CXB3, HCV, and Ad5 displayed very similar numbers and qualities of matches to cardiac proteins, squarely between SARS-CoV-2 and influenza viruses. Because adenovirus vectors have been used to deliver some SARS-CoV-2 vaccines, and these vaccines have been found to have some risk of inducing cardiopathies (see Introduction), Figure 5 illustrates some of the best quality matches between Ad5 proteins and cardiac proteins.

Table 2. Statistics comparing the significance of the total number of matches of SARS-CoV-2 (SARS) to the number of similarities to cardiac proteins from Figure 4 to those of control viruses: coxsackievirus type B3 (CoxB3); hepatitis C virus (HepC); poliovirus (polio); influenza A H1N1 (INFA); and adenovirus type 5 (Ad5). The total number of matches meeting the criterion of greater than 5 of 10 identical amino acids in a sequence of ten is provided under each virus name (“ID > 5 of 10”). A student’s paired T-test was used to compare the paired combinations. Because every possible combination was compared, a Bonferroni correction was applied such that for a difference to be significant, the *p* value needed to be less than 0.005 (indicated with a *).

	CoxB3 58	HCV 66	Polio 53	INFA 0	Ad5 80
SARS 202	t = 5.27 p < 0.0001 *	t = 4.16 p = 0.0007 *	t = 6.74 p < 0.0001 *	t = 7.09 p < 0.0001 *	t = 4.73 p = 0.0002 *
CoxB3 58		t = 0.38 p = 0.71	t = 0.48 p = 0.64	t = 3.53 p = 0.0026 *	t = 1.68 p = 0.11
HCV 66			t = 0.65 p = 0.52	t = 3.90 p = 0.0010 *	t = 0.86 p = 0.40
Polio 53				t = 3.42 p = 0.0032 *	t = 2.14 p = 0.05
INFA 0					t = 5.41 p < 0.0001 *

Table 3. Statistics comparing the significance of the number of high-quality SARS-CoV-2 (SARS) similarities to cardiac proteins to those of control viruses: coxsackievirus type B3 (CoxB3); hepatitis C virus (HepC); poliovirus (polio); influenza A H1N1 (INFA); and adenovirus type 5 (Ad5). The total number of matches that had an E score of 60 or greater (“E Score > 59”) is provided under each virus name. A student’s paired T-test was used to compare the paired combinations. Because every possible combination was compared, a Bonferroni correction was applied such that in order for a difference to be significant, the *p* value needed to be less than 0.005 (indicated with a *).

E Score >59	CoxB3 9	HCV 24	Polio 10	INFA 0	Ad5 48
SARS 73	t = 3.55 p = 0.0024 *	t = 2.39 p = 0.03	t = 3.53 p = 0.0026 *	t = 4.01 p = 0.0009 *	t = 1.32 p = 0.21
CoxB3 9		t = 1.05 p = 0.31	t = 0.0000 p = 1.00	t = 2.03 p = 0.06	t = 3.27 p = 0.0045 *
HCV 24			t = 1.03 p = 0.32	t = 1.71 p = 0.11	t = 2.14 p = 0.05
Polio 10				t = 2.60 p = 0.02	t = 3.47 p = 0.0029 *
INFA 0					t = 3.96 p = 0.0010 *

	SARS-CoV-2	CoxB3	HCV	Polio viruses	INF A H1N1	Adeno-viruses	Strep. pneum.	Kleb. pneum.	Staph. aureus	Enter. faecium
>6 of 10/6 of 10 E>70/E>60<70	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60
P13533 Cardiac myosin	3/11 1/6	1/13 0/2	1/6 0/2	1/6 0/4	0/0 0/0	3/7 1/4	7/28 35/0	18/25 2/7	3/10 1/3	0/13 1/2
P68032 Cardiac actin	1/12 1/1	0/0 0/0	0/2 0/0	1/5 0/0	0/0 0/0	0/4 0/1	3/8 0/3	11/23 1/4	3/9 0/3	1/5 0/0
P02452 Collagen 1 alpha	2/6 0/4	3/5 0/0	1/14 0/6	0/5 0/1	0/0 0/0	4/0 1/3	2/2 1/0	6/14 1/3	1/3 0/0	1/5 0/0
P02461 Collagen III	2/9 1/7	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	5/2 7/0	3/10 0/0	2/15 0/0	1/1 0/1	1/6 0/0
P53420 Collagen IV	1/17 1/3	0/6 0/1	2/16 6/7	1/5 1/0	0/0 0/0	1/7 3/5	4/10 0/1	4/23 0/2	1/0 0/1	1/4 0/0
P25391 Laminin 1	3/27 0/7	1/7 0/4	0/1 0/0	3/6 0/2	0/0 0/0	1/6 0/2	0/4 1/2	9/17 0/3	4/7 1/3	7/31 0/3
Q16363 Laminin 4	4/14 5/13	0/4 0/0	0/4 1/2	4/6 0/0	0/0 0/0	3/8 2/4	0/4 0/3	10/13 4/9	2/12 1/2	6/16 0/0
P08588 Beta 1 ADR	0/3 0/0	0/1 0/1	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/3 0/1	4/8 0/3	4/5 2/0	0/6 0/0
P07550 Beta 2 ADR	3/12 1/3	0/2 0/0	0/1 0/0	0/0 0/0	0/0 0/0	2/5 0/2	2/8 0/2	4/16 0/4	1/6 0/2	1/8 0/1
P35348 Alpha 1A ADR	0/8 0/1	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	2/9 1/2	4/18 0/5	1/2 0/1	2/9 0/1
P06732 Creatine Kinase M	0/6 0/0	0/0 0/0	1/1 0/0	0/0 0/0	0/0 0/0	2/4 2/2	3/16 0/5	6/24 0/3	2/2 4/0	0/6 0/0
P14618 Pyruvate Kinase M	1/5 0/0	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	4/17 0/7	6/23 1/5	15/0 15/0	1/12 0/0
P78310 CXADR	2/8 0/3	0/3 0/1	2/3 0/0	0/1 0/0	0/0 0/0	1/8 0/1	0/1 0/0	2/13 0/0	0/1 0/0	0/10 0/0
Q9BYF1 ACE2	1/15 1/6	0/0 0/0	0/1 0/0	0/0 0/0	0/0 0/0	1/3 0/2	4/3 0/2	6/21 0/6	1/2 0/2	0/12 0/0
P02749 β 2GPI	0/5 0/1	0/1 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/0 0/0	0/7 0/0	5/17 0/2	1/5 0/1	0/8 0/1
P06733 Alpha-enolase	0/10 0/3	0/0 0/0	1/0 0/0	0/0 0/0	0/0 0/0	1/1 1/0	10/7 17/0	17/6 23/0	13/5 18/0	2/13 0/2
P13805 Troponin	0/2 0/0	0/5 0/0	0/2 0/0	0/2 0/1	0/0 0/0	3/5 6/2	0/9 0/1	2/9 0/2	0/4 0/3	1/7 1/0
P08174 CD55/DAF	3/6 1/5	1/4 0/0	1/6 0/0	1/5 0/1	0/0 0/0	0/0 0/0	0/4 0/1	7/9 2/3	0/2 0/2	0/2 0/0
TOTALS	24/178 11/62	6/52 0/9	9/57 7/17	11/41 1/9	0/0 0/0	23/57 22/26	44/150 55/30	123/291 34/61	53/76 42/26	24/173 2/10

Figure 4. Summary of similarities between microbes associated with COVID-19 and human cardiac proteins. See Figure 1 for an explanation of the arrangement of numbers in each box. The bolded numbers are significantly different from the rest of the results.

Adenovirus 5 Similarities to Human Heart Proteins

Cardiac Actin P68032 vs Adenovirus 5

WE 54; 20.0 bits; E(1) < 0.99
 ACTIN IKEKLCYVALDFE 214-226
 ||| | | ||| :
 Adenov IKETLDYCALDVQ 2387-2399

Cardiac Myosin P13533 vs Adenovirus 5

WE 66; 23.7 bits; E(1) < 0.86
 (Overlap 1117-1146 | 3478-3507)
 MYOSIN EEEEELEAERTARAKVEKLRSDELSRELEE
 ||:|||| | : \:| :| | |||
 Adenov EEIEEEEEAPVAFEREVRDTVAELIRLLEE

 WE 65; 23.4 bits; E(1) < 0.91
 MYOSIN RVKKKMEGDLNEM--EIQLSHA 1615-1634
 ||||| : | :|: | :| ||
 Adenov RVKKKKDDDDDELDEVELLHA 5770-5791

WE 63; 22.7 bits; E(1) < 0.98
 MYOSIN QTENGELARQLEEKEALISQ 1283-1302
 ::|: :| | :|||: |||:|:
 Adenov KSSED-QLRRTLEDAEALFSK 9457-9476

WE 62; 22.4 bits; E(1) < 0.99
 MYOSIN ERSNAAAAAL 1435-1444
 |:|||||||:
 Adenov ENSNAAAAAM 5195-5204

WE 59; 21.5 bits; E(1) < 1
 MYOSIN RAQLEFNQIKA 1562-1572
 :||: |:||||
 Adenov KAQVAFKQIKA 8193-8203

B2AR P07550 vs Adenovirus 5

WE 67; 25.1 bits; E(1) < 0.14
 B2AR NGSHAPDHDVTQERDE 15-30
 | : ||:|||||:|:
 Adenov NPTVAPTHDVTTRDSQ 6615-6630

WE 54; 20.8 bits; E(1) < 0.95
 B2AR NWIGYVNSGFN 312-322
 | :|| |||||:
 Adenov NSTGYSNSGFS 10204-10214

WE 52; 20.2 bits; E(1) < 0.99
 B2AR ITSPFKYQSLLT-KNKARVIL 135-155
 |::| : :||:| || :| |||
 Adenov IDAPTRANSLATIKNMIRYIIL 10294-10314

ACE2 Q9BYF1 vs Adenovirus 5

WE 67; 24.5 bits; E(1) < 0.37
 (Overlap 411-440 | 11243-11269)
 ACE2 SAATPKHLKLSIGLLSPDFQEDNETEINFL
 |:|| |::| :| | ||:|:| | |
 Adenov SLATIKNMKIVG---ADGQEQEETDIPFRL

WE 60; 22.2 bits; E(1) < 0.89
 ACE2 LTAHHEMGHIQYDMAYAAQPFLLRNG 370-395
 :| | :|:| : | | |||:|
 Adenov ITQGHILGQLQ-AINKARQEFLLRKG 9055-79

WE 56; 20.9 bits; E(1) < 1
 ACE2 EHTFEEI 226-232
 ||||:|
 Adenov EHTFQEI 4518-4524

WE 58; 21.6 bits; E(1) < 0.97
 (Overlap 54-82 | 8119-8147)
 ACE2 ITEENVQNMNAGDKWSAFLKEQSTLAQM 54-82
 |::|:| | : : : | |||:|:
 Adenov INKEHVIEMDVTSENGQRLKEQSSKAKI

Troponin P13805 vs Adenovirus 5

WE 104; 32.7 bits; E(1) < 0.00052
 TROPON EPEPVAEPEEERPKPSRPVPLI 27-51
 |||| ||| || | : | |
 Adenov EPEPEPEPEPARPT-RRPKMAPAI 200-224

WE 95; 30.2 bits; E(1) < 0.003
 TROPON TEEQEYEEEPPEEAAEEEE 4-24
 |:|:| | : | | | : |||:
 Adenov TDEEYWDSQAEVLDDEEED 9541-9561
 Repeated at 5217-5250; 9269-9295, 9290-9312, 9550-9590

WE 77; 25.2 bits; E(1) < 0.094
 TROPON QEYEEEPPEEAAEEEEEP 8-26
 :| | | || :||| |||
 Adenov EEEEGEALMEEEIEEEEEAP 3468-3467

WE 68; 22.7 bits; E(1) < 0.43
 110
 TROPON IERRRSERAEQQRFRTE 103-119
 :|||: ||||:|:
 Adenov LERRRAA-AEQQRMNQE 11032-11049

Collagen 1 P02452 vs Adenovirus 5

WE 87; 28.2 bits; E(1) < 0.063
 COLL1 PPGPAGQDGRPGPPGPPGAR 555-574
 || ||| | || |||||
 Adenov PPLPAG---PEPPLPPGAR 3721-3736

WE 78; 25.9 bits; E(1) < 0.28
 COLL1 PGLPGPPGPPGPPG 138-151
 | ||: | || |||
 Adenov PPLPAGPEPPLPPG 3721-3734

WE 77; 25.6 bits; E(1) < 0.32
 COLL1 PPGPPGPPGPPGPPSA 1179-1194
 || | || || || |
 Adenov PPLPAGPE-PPLPPGA 3721-3735

WE 76; 25.3 bits;
 Overlap (623-650|1849-1875)
 COLL1 GPAGPAGERGEQGPAGSPGFQGLPGPAG
 :|| || | :|| ||| :|:| :|
 Adenov APA-PARARRRAPAPSPGGSGAPPTSG

Figure 5. Examples of LALIGN-derived similarities between adenovirus type 5 and human cardiac proteins. WE stands for Waterman-Eggert score (the larger the score, the less likely the similarity is due to chance). E is a measure of probability inverse to the WE score, so the smaller E, the less likely the match is due to chance. The numbers following the protein name are the UniProtKB identifiers. Numbers following the sequences (or preceded by “overlap”) define the place of the sequence in the amino acid sequence of the protein.

2.3. Proteomic Study of Similarities Shared by Bacterial and Human Cardiac Proteins

Since severe COVID-19 patients are at higher risk for AD than mild cases, and since severe cases are much more likely to contract bacterial co- or super-infections (see Introduc-

tion), an analysis of possible similarities between the most common COVID-19 bacterial co- and super-infections and human cardiac proteins was performed. The LALIGN approach of comparing each cardiac protein to each virus protein was not possible since bacteria have thousands of proteins. Instead, each cardiac protein was compared to the total bacterial species' proteomes using BLASTP. The same criteria utilized above were used here to evaluate significance: Only matches that had a Waterman-Eggert score of at least 50, an E value of less than 1.0, and contained a sequence of ten amino acids in which at least six were identical were counted as sufficiently similar to induce possible cross-reactive immunity; this criterion is based on substantial research demonstrating that sequences exhibiting at least this degree of similarity have a >85% probability of being cross-reactive under experimental conditions [58–61].

Figure 4 summarizes the results, while Figures 6–9 provide examples of the matches found. These matches were often of better quality than the virus matches, both in terms of the number of identical amino acids in any given sequence and in terms of the length of the sequences.

***Streptococcus pneumoniae* Similarities to Human Cardiac Myosin**

***Streptococcus pneumoniae* Nucleotide-binding protein SPH_1680 B1ICY6.1, C1CFE9.1, C1C8F7.1, C1C8F7.1, etc. vs. human cardiac myosin P13533**

MYOSIN 166 LTDRENQSILITGESGAGKTV 186
+T ++ + +++TG SGAGKTV
S.pneum 1 MTKKQLHLVIVTGMMSGAGKTV 21

***Streptococcus pneumoniae* Elongation factor G; C1CIF3.1 vs human cardiac myosin P13533**

MYOSIN 1256 DQANEYRVKLEEA 1268
DQA+EYR KL EA
S.pneum205 DQAQEYREKLVEA 217

***Streptococcus pneumoniae* Oligopeptide transport ATP-binding protein AmiE P0A2U8.1 vs human cardiac myosin P13533**

MYOSIN 170 ENQSILITGESGAGKTVNTK 189
E + ++++GESG+GK+V TK
S.pneum 37 EGEVLALVGESGSGKSVLTK 56

***Streptococcus pneumoniae* Toxin PezT; Q97QZ1.1 vs human cardiac myosin P13533**

MYOSIN 173 SILITGESGAGKT 185
+IL+ G+SGAGKT
S.pneum 34 AILLGGQSGAGKT 46

MYOSIN 489 FFNHHMFVLE-QEYKKEGIEWT 510
F ++H + LE Q+EY K+ +E+T
S.pneum 68 FRSQHPHYLELQQEYGKDSVEYT 90

***Streptococcus pneumoniae* TIGR4 UvrABC system protein A P63384.1 vs human cardiac myosin P13533**

MYOSIN 314 VSQGEVSVASIDDSEELMATDSAFDVLGFTSEE 346
+++G V + ++DDSE L + A V GFT E
S.pneum 228 IAEGYVIIDTMDDSELLFSEHYACPVCGFTVPE 260

***Streptococcus pneumoniae* TIGR4Transport protein ComB P36498.4 vs human cardiac myosin P13533**

MYOSIN 50 KILSREGGKVIAET--ENGKTVTVKEDQVLQQNP 80
KIL+ E GK + + + GK VT ED VL+ NP
S.pneum 291 KILEAESGKKVQGNLLDKGK-VTASEDGVHLNLP 319

Figure 6. Examples of BLASTP-derived similarities between *Streptococcus pneumoniae* proteins and cardiac myosin. Plus signs (+) indicate conserved amino acid substitutions. Numbers following the protein name are the UniProtKB identifiers. The numbers before and after the sequences define the place of the sequence in the amino acid sequence of the protein.

Figure 7. Examples of BLASTP-derived similarities between proteins of bacteria associated with COVID-19 collagen type 1 alpha. Plus signs (+) indicate conserved amino acid substitutions. Numbers following the protein name are the UniProtKB identifiers. The numbers before and after the sequences define the place of the sequence in the amino acid sequence of the protein.

Human Alpha Enolase (P06733) vs *Staphylococcus aureus* Laminin-Binding Protein (O69174.1)

Enolase	3	ILKIHAREIFDSRGNPTVEVDLFTSKGLF-RAAVPSGASTGIYEALERDNDKTRYMGKG	61
		I ++ARE+ DSRGNPTVEV++ T G F RA VPSGASTG +EA+ELRD DK+RY+GKG	
S.aureus	4	ITDVYAREVLDNRGNPTVEVLTESGAFGRALVPSGASTGEHEAELRDGDKSRYLKGG	63
Enolase	62	VSKAVEHINKTIAPALVSKKLVNTEQEKIDKLMIEDGTENKSKFGANAILGVSLAVCKA	121
		V+KAVE +N+ IAP ++ + V +Q IDK+MI +DGT NK K GANAILGVSAV +A	
S.aureus	64	VTKAVENVNEIIAPEIIEGEFSVLDQVSIDKMMIALDGTNPNGKLGANAILGVSLAVARA	123
Enolase	122	GAVEKGVPLRYHIADLAGNSEVILPVPFNVINGGSHAGNKIAMQEFMILPVGAANFREA	181
		A G PLY+++ G LPVP N++NGGSH+ +A QEFMILPVGA F+E+	
S.aureus	124	AADLLGQPLYKYLGGFNGKQ---LPVPMNIVNGGSHSDAPIAFQEFMILPVGATTFKES	180
Enolase	182	MRIGAEVYHNLKNVIKEKYKDATNVGDEGGFAPNILENKEGLELLKTAIGKAGYT--DK	239
		+R G E++HNLK ++ ++ G + T VGDEGGFAP ++ +E + AI AGY ++	
S.aureus	181	LRWGTETIFHNLKLSILSQR-GLE-TAVGDEGGFAPKEGTEGDAVETIIQAIEAAGYKPGEE	238
Enolase	240	VVIGMDVAASEFFRSRGKYDLDFKSPDDPSRYISPDQLADLYKSFIDYPPVSIEDPFDQ	299
		V +G D A+SEF+ G YD + ++ + +Q+ D + + YP+++IED D++	
S.aureus	239	VFLGFDCASEFYENGVDYDYSKFEHGAKRATAEQV-DYLEQLVDKYPITIEDGMDEN	297
Enolase	300	DWGAWQKFTASAG--IQVVGDDLTVTNPKRIAKAVNEKSCNCLLLKVNQIGSVTESLQAC	357
		DW W++ T G +Q+VGDDL VTN + +AK + N +L+KVNQIG++TE+ A	
S.aureus	298	DWDGWQLTERIGDRVQLVGDDLFVTNTILAKGIENGIGNSILIKVNQIGTLTETDAI	357
Enolase	358	KLAQANGWGMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLLRIEEEL	417
		++AQ G+ +VSHRSGETEDT IAD+ V GQIKTG+ R++R+AKYNQLLRIE+EL	
S.aureus	358	EMAQKAGYTAVVSHRSGETEDTTIADIAVATNAGQIKTGSLSRTDRIAKYNQLLRIEDEL	417
Enolase	418	GSKAKFAG-RNFRN	430
		AK+ G + F N	
S.aureus	418	FETAKYDGIKSFYN	431

Human Alpha Enolase (P06733) vs *Klebsiella pneumoniae* Phosphoglycerate Dehydratase (A6TD53.1)

Enolase	3	ILKIHAREIFDSRGNPTVEVDLFTSKGLF-RAAVPSGASTGIYEALERDNDKTRYMGKG	61
		I+K+ REI DSRGNPTVE ++ G AA PSGASTG EALELRD DK+R++GKG	
K.pneum	4	IVKVIGREIIDSNGNPTVEAEVHLEGGFVGMMAAPSGASTGSREALELRDGDGKSRFLGKG	63
Enolase	62	VSKAVEHINKTIAPALVSKKLVNTEQEKIDKLMIEDGTENKSKFGANAILGVSLAVCKA	121
		V+KAV +N IA A++ K + +Q IDK+MI++DGTENKS FGANAIL VSLA KA	
K.pneum	64	VTKAAVAVNGPIAQAILGK--DAKDQAGIDKIMIDLDTGTENKSNFGANAILAVSLANAKA	121
Enolase	122	GAVEKGVPLRYHIADLAGN-SEVILPVPFNVINGGSHAGNKIAMQEFMILPVGAANFREA	180
		A KG+PLY HIA+L G + +PVP N+INGG HA N + +QEFMI PVGA +E	
K.pneum	122	AAASKGLPLYAHIAELNGTPGKYSMPVPMNIINGGEHADNVDIQEFMIQPVGAPTLEKE	181
Enolase	181	AMRIGAEVYHNLKNVIKEKYKDATNVGDEGGFAPNILENKEGLELLKTAIGKAGYT--D	238
		A+R+G+EV+H L V+K K G + T VGDEGG+APN+ NE L ++ A+ AGY	
K.pneum	182	AVRMGSEVFHHLAKVLKSK-GMN-TAVGDEGGYAPNLGSNAEALAVIAEAVKAAGYELGK	239
Enolase	239	KVIGMDVAASEFFRSRGKYDLDFKSPDDPSRYISPDQLADLYKSFIDYPPVSIEDPFDQ	298
		+ + MD AASEF++ GKY L + + + ++ + K YP+VSIED D+	
K.pneum	240	DITLAMDCAASEFYKDGKYVL---AGEGNKAFTESEFTHFLEELTKQYPIVSIEDGLDE	295
Enolase	299	DDWG--AWQKFTASAGIQVVGDDLTVTNPKRIAKAVNEKSCNCLLLKVNQIGSVTESLQA	356
		DW A+Q IQ+VGDDL VTN K + + + + N +L+K NQIGS+TE+L A	
K.pneum	296	SDWEGFAYQTKVLGDKIQLVGDDLFVTNTKILKEGIEKGIANSILIKFNQIGSLTETLAA	355
Enolase	357	CKLAQANGWGMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLLRIEEE	416
		K+A+ G+ ++SHRSGETED IADL VG GQIKTG+ RS+R+AKYNQL+RIEE	
K.pneum	356	IKMAKDAGYTAVISHRSGETEDATIADLAVGTAGQIKTGSMRSRDRVAKYNQLIRIEEA	415
Enolase	417	LGSKAKFAGR	426
		LG +A F GR	
K.pneum	416	LGEQAPFNGR	425

Figure 8. Examples of BLASTP-derived similarities between proteins of bacteria associated with COVID-19 and human alpha enolase. Actually, both proteins are phosphoglycerate dehydratases that also go by the name “laminin-binding protein”. Plus signs (+) indicate conserved amino acid substitutions. Numbers following the protein name are the UniProtKB identifiers. The numbers before and after the sequences define the place of the sequence in the amino acid sequence of the protein.

Human Pyruvate Kinase (P14618) vs. *Staphylococcus aureus* subsp. aureus MRSA252] Sequence ID: Q6GG09.1

	Score	Expect	Method	Identities	Positives	Gaps
	410 bits(917)	4e-123	Compositional matrix adjust.	217/488(44%)	305/488(62%)	23/488(4%)
PyKin 43	RNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSGHGTHEYHAETIKNVRTATESFASDP	102				
S.aur 2	R T I+CTIGPAS S E ++++I +GMNVARLNFSGH+HE H I +R + D RRTKIVCTIGPASESEEMIEKLINAGMNVARLNFSGHSHEEHKGRIDTIRKVAKRL--DK	59				
PyKin 103	ILYRPVAVALDTKGPEIRTGLIKSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYK	162				
S.aur 60	I VA+ LDTKGPEIRT +K G +EL++G + ++++ +E E + Y+ I----VAILLDTKGPEIRTHNMK-DGI--IELERGNEVIVSMNE--VEGTPEK-FSVTYE	109				
PyKin 163	NICKVVEVGSKIYVDDGLISLQVKQ--KGADFLVTEVENGGSLGSKKGVNLPGAADVLP	220				
S.aur 110	N+ V+VGS I +DDGLI LQVK + ++ N G L KKGVNLP G V LP NLINDVQVGSYILLDDGLIELQVKDIDHAKKEVKCDILNSGELKNKGVNLP GVRVSLPG	169				
PyKin 221	VSEKDIQDLKFGVEQDVMVFASFIRKASDVHEVRKVLGEKGNIKIISKIENHEGVRRF	280				
S.aur 170	++EKD +D++FG++++VD + ASF+R+ SDV E+R++L E+ NI + KIEN+EG+ ITEKDAEDIRFGIKENVDFIAASFVRRPSDVLIREILEEQKANISVFPKIENQEGIDNI	229				
PyKin 281	DEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLSEMIKKPRP	340				
S.aur 230	+EILE SDG+MVARGD+G+EIP EKV + QK +I +CN+ GKPVI ATQML+SM + PR EEILEVSDGLMVARGDMGEIPPEKVPVQKDLIRQCCKLGPVITATQMLDSMQRNPR	289				
PyKin 341	TRAEAGSDVANAVLDGADCMISGETAKGDYPLEAVRMQHIAAREAAAIYHLQFEELRR	400				
S.aur 290	TRAE SDVANA+ DG D +MLSGETA G YP EAV+ IA AEAA + +L + + TRAEASDVANAIYDGTDAVMSGETAAGLYPEEAVKTMRNIAVSAEAAQDYKKLLSDRTK	349				
PyKin 401	LAPITSDPTEATAVGAVEASFCKCSGAIIVLTSGRSRSHQVARYRPRAPIIAVTRNPQTA	460				
S.aur 350	L + + A + + AI+ T+SG +A +++YRP + IIAVT +TA L--VETSLVNAIGISVAHTALNLNVKAIVAATESGSTARTISKYRPHSDIIIAVTPSEETA	407				
PyKin 461	RQAHLYRGIFPVLCKDPVQEAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPG-S	519				
S.aur 408	RQ + G+ PV+ K + D +N A+ G GD++I+ G G + RQCSIVWGVQPVVKK-----GRKSTDALLNNAVATAVETGRVTNGDLIIITAGVPTGET	461				
PyKin 520	GFTNTMRV 527					
S.aur 462	G TN M++ GTTNMMKI 469					

Figure 9. Example of BLASTP-derived similarities between proteins of methicillin-resistant *Staphylococcus aureus* and human pyruvate kinase. Plus signs (+) indicate conserved amino acid substitutions. Numbers following the protein name are the UniProtKB identifiers. The numbers before and after the sequences define the place of the sequence in the amino acid sequence of the protein.

Overall, the bacteria were more likely than the viruses to mimic myosin, actin, collagens, β 2GPI, and the enzymes alpha enolase, creatine kinase, and pyruvate kinase, and the similarities tended to be more extensive than those displayed by the viruses (Figures 4 and 6–9). The mimicry between the Streptococcal M protein (omitted in Figure 6, which emphasizes additional potential myosin mimics) has been extensively studied previously and employed as the basis for numerous animal models of rheumatic heart disease and autoimmune myocarditis [69–72]. However, it is notable that other bacteria, including *Enterococcus faecium*, *Staphylococcus aureus*, and *Klebsiella pneumoniae*, also displayed many significant similarities to cardiac myosin (Figure 4) that might also play roles in triggering autoimmune cardiopathies. The clinical picture is, however, somewhat confused by the fact that cytotoxic antibodies targeting the Streptococcal M protein and cross-reacting with cardiac myosin also cross-react with enteroviruses such as polio and coxsackieviruses [73–75]. In light of the data presented in Figure 4 that coxsackieviruses, polioviruses, and *Streptococci* each have proteins that mimic cardiac myosin, this cross-reactivity is perhaps not surprising.

In sum, the similarity searches yielded the interesting result that both viruses (especially SARS-CoV-2 and adenovirus type 5) and bacteria associated with severe COVID-19 displayed large numbers of high-quality and often extensive sequences of similarity with human cardiac proteins. Thus, both viral and bacterial antigens might play roles in trigger-

ing autoimmunity in COVID-19. The fact that coxsackieviruses, polioviruses, and HCV also display many cardiac protein similarities and are associated with some risk of autoimmune myocarditis is also consistent with these proteomic results.

2.4. Experimental Results of Virus Antibody Binding to Cardiac Proteins Using ELISA

To test the utility of the similarity results, polyclonal antibodies against viruses and bacteria associated with COVID-19 (e.g., SARS-CoV-2, adenoviruses, *Streptococci*, *Staphylococci*, *Enterococci*), and a random selection of microbes not associated with COVID-19 (e.g., influenza, coxsackieviruses, herpes simplex type 1, *Clostridia*, and *Mycobacterium tuberculosis*) were tested for their binding to cardiac proteins using quantitative ELISA.

The results of the virus antibody experiments are summarized in Table 4, and examples of the binding curves obtained are shown in Figures 10–12. Most of the observed binding involved the SARS-CoV-2 spike protein or nucleoprotein. Unfortunately, no polyclonal antibodies were available against the replicase, which also displayed a large number of high-quality similarities to cardiac proteins in the similarity searches above. Among the control viruses, several induced antibodies that recognized myosin and adenovirus antibodies also recognized laminin, fibronectin, and creatine kinase. Coxsackievirus antibodies were notable for binding to myosin and laminin. Also notable is the result that no virus antibody tested bound to cardiolipin, although anti-cardiolipin antibodies are one of the most common found in COVID-19 patients with autoimmune cardiopathies (see Introduction).

Table 4. Summary of quantitative ELISA experiments involving the binding of polyclonal antibodies against virus antigens to cardiac proteins and cardiolipin. Numbers are binding constants derived from the inflection points of the binding curves, examples are shown in Figures 11–13. Coll 1 = collagen type 1; Coll IV = collagen type IV; Fibro = fibronectin; Inv = Invitrogen; Mab = monoclonal antibody (mouse); HSV1 = human herpes simplex virus type 1. * Human actin only; no binding to porcine actin.

SARS-CoV-2	Cardio-lipin	Myosin	Actin	Coll I	Coll IV	Laminin	Fibro	B2AR	Creatine Kinase	Pyruvate Kinase
Spike 1 (Millipore)	>100 μ M	220 nM	>1 μ M	8 nM	10 nM	1 μ M	>1 μ M	100 nM	60 nM	300 nM
Spike Protein (Inv)	>100 μ M	10 nM	>1 μ M	>1 μ M	>1 μ M	>1 μ M	2 nM	300 nM	--	--
S2 (Millipore)	>100 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	50 nM	>10 μ M	>1 μ M
RBD (Millipore)	>100 μ M	>1 μ M	>1 μ M	4 nM	>1 μ M	10 nM	>1 μ M	>1 μ M	>10 μ M	>1 μ M
Envelope (Inv)	>100 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>10 μ M	>1 μ M
Matrix (Inv)	>100 μ M	300 nM	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>10 μ M	>1 μ M
Nucleoprotein (Inv)	>100 μ M	>1 μ M	>1 μ M	5 nM	20 nM	>1 μ M	>1 μ M	>1 μ M	700 nM	400 nM
OTHER VIRUSES										
Adenovirus	>100 μ M	7 nM	>1 μ M	>1 μ M	>1 μ M	2 nM	8 nM	>1 μ M	1.5 nM	>1 μ M
Influenza A	>100 μ M	50 nM	>1 μ M	>1 μ M	2 nM	>1 μ M	>1 μ M	>1 μ M	>10 μ M	>1 μ M
Coxsackie B MAb mix	>100 μ M	50 nM	>1 μ M	>1 μ M	>1 μ M	100 nM	>1 μ M	>1 μ M	--	--
Coxsackie B3 Monkey	>100 μ M	30 nM	0.7 nM *	>1 μ M	2 nM	>1 μ M	0.8 nM	>1 μ M	>10 μ M	1 μ M
HSV1	>100 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>10 μ M	100 nM

The first set of experiments that we performed determined whether it was possible to substitute non-human proteins for human proteins in these studies, and, with one exception (actin, which is noted in the results that follow), the SARS-CoV-2 antibodies employed here bound (or did not bind) equally to both human- and animal-derived proteins. Thus, most of the studies were carried out with non-human proteins because they were available in greater quantities at lower prices.

Note that in order to interpret the significance of the binding constants derived from the curves illustrated in Figures 11–13 (and in the Figures that follow in the next section), it is necessary to compare the binding constants to the concentration of cardiac protein present either in the heart or in blood serum. The relevant data are summarized in Table 5. As a general rule, the binding constant should be equal to or smaller than the concentration of the protein for the antibody to bind sufficient protein to impair its function or induce

complement activation to cause cellular damage. Binding constants in Figure 10 that satisfy these criteria are bolded on a gray background, and the same formalism is used in the next section as well.




Figure 10. (Left) Quantitative ELISA binding curves for SARS-CoV-2 antibodies binding to creatine kinase (CK) and pyruvate kinase (PK). S1-CK = SARS-CoV-2 spike protein S1 fragment antibody binding to CK; S2 = SARS-CoV-2 spike protein fragment S2 antibody; RBD = SARS-CoV-2 spike protein RBD fragment antibody. (Right) Comparison of Influenza A antibody (Inf A), Adenovirus antibody (Aden), *Streptococcal* antibody (Strep), *Staphylococcal* antibody (Staph), and *Escherichia coli* (*E. coli*) antibody binding to creatine kinase (CK).




Figure 11. (Left) Quantitative ELISA results showing binding of SARS-CoV-2 envelope (Env), matrix, nucleoprotein (NP), and spike protein (SP) polyclonal antibodies binding to collagen type 1 (Collagen 1) compared with binding of some bacterial antibodies. (Right) SARS-CoV-2 spike protein fragment S1, S2, or RBD antibodies and adenovirus antibodies to fibronectin. MP = Millipore.




Figure 12. (Left) Quantitative ELISA results showing binding of SARS-CoV-2 nucleoprotein (NP), spike protein (SP), or spike protein S1 fragment (S1) antibodies to actin compared with antibodies against Clostridia and Mycobacterium tuberculosis. (Right) SARS-CoV-2 nucleoprotein (NP), spike protein fragment S1 (SP1), fragment S2 (SP2), or fragment RBD binding to cardiac myosin compared with human herpes simplex type 1 (HSV1) antibody binding. MP = Millipore; Inv = Invitrogen.




Figure 13. (Left) Results of quantitative ELISA experiments involving the binding of bacterial antibodies to myosin. *E. coli* = *Escherichia coli* antibody; *M. tuberculosis* = *Mycobacterium tuberculosis* antibody. (Right) Results of quantitative ELISA experiments involving binding of microbial antibodies to beta 2 glycoprotein I ($\beta 2\text{GPI}$). The double curve for Staphylococcus binding may indicate both a high-affinity and a lower affinity binding site. SP1 = spike protein fragment 1; SP2 = spike protein fragment 2; RBD = spike protein RBD fragment; NP = nucleoprotein; MP = Millipore.

Table 5. Physiological concentrations of cardiac proteins [75–90]. The numbers in brackets refer to the references. * = healthy heart but micromolar actin found in severe lung injury, sepsis, etc. [89,90]; ^ = range from healthy (0) to severe myocarditis (250 nM) [86]; Conc. = concentration; # Calculated as follows: 5000 units/mg pyruvate kinase (PK) activity [87] and 12–46 U/mL in serum from heart failure patients [88], and molecular weight (MW) if PK is 57 kD/chain. So 50 U/mL = 0.2 mg/mL = 0.2 μ M; is ~ calculated from total hydroxyproline in the heart, which is 3 mg/gram of tissue, and the MW of collagen is 300 kD, so 3 mg/g = 10 μ M [79], and collagen I makes up 80% of heart collagen; collagen III, 11%; and collagen IV, about 5% [80].

	Significant K _D Found Here	Normal Serum Conc.	Heart Conc.	Source
Actin	10 nM	0 *	2 μ M	[75]
Beta 2 Adrenergic Receptor	50 nM	n/r	15 nM	[76]
Cardiolipin	400 nM–2 μ M	10 μ M	1.6 μ M	[77,78]
Collagen I Fibrillar	4–8 nM	n/r	8 μ M ~	[79,80]
Collagen III Fibrillar	--	n/r	1 μ M ~	[79,80]
Collagen IV Basement Membrane	2–20 nM	n/r	0.5 μ M ~	[79,80]
Creatine Kinase	60 nM	20–50 nM	40–60 nM	[81,82]
Fibronectin	0.3–100 nM	1–3 μ M	0.5 μ M	[83,84]
Laminins	0.8–100 nM	n/r	0.2–0.4 μ M	[85]
Myosin	3–50 nM	0–250 nM ^	1 μ M	[82,86]
Pyruvate Kinase	100 nM	50–200 nM #	50–200 nM #	[87,88]

2.5. Experimental Results of Bacterial Antibody Binding to Cardiac Proteins Using ELISA

Bacterial antibodies against *Staphylococcus aureus*, *Streptococci*, *Klebsiella pneumoniae*, *Escherichia coli*, *Clostridia*, *Mycobacterium tuberculosis*, and *Enterococcus faecium*, all of which are common co-infections in severe COVID-19 (see Introduction), were also tested for binding to cardiac proteins using the same quantitative ELISA protocol used to test the virus antibodies. The results are summarized in Table 6, and some of the binding curves are illustrated in Figure 10(Right), Figure 11(Left) and Figure 12(Left) above and in Figures 13 and 14 below. *Streptococci*, *Staphylococci*, *Klebsiella*, and *Enterococci* antibodies were notable for high affinity binding to cardiolipin and pyruvate kinase, to which none of the SARS-CoV-2 or other virus antibodies bound significantly, as well as to myosin. None of the bacterial antibodies bound with significant affinity to B2AR or creatine kinase, which were targets of some of the SARS-CoV-2 and adenovirus antibodies (Figure 10). Since all of these proteins are targets of autoimmunity in some forms of COVID-19 autoimmune cardiopathies, these differences in virus and bacteria cross-reactivities may be important for understanding the microbial triggers involved in eliciting autoantibodies against different cardiac proteins.

Table 6. Summary of quantitative ELISA experiments involving the binding of polyclonal and monoclonal antibodies against bacterial antigens to cardiac proteins and cardiolipin. Numbers are binding constants derived from the inflection points of the binding curves, examples are shown in Figure 11(Right), Figure 12(Left), Figure 13(Left), Figures 15 and 16. Coll 1 = collagen type 1; Coll IV = collagen type IV; Fibro = fibronectin; Inv = Invitrogen; Mab = monoclonal antibody (mouse); *S. aureus* = *Staphylococcus aureus*; GAS = group A *Streptococci*; Strep = *Streptococcus pneumoniae*; *E. coli* = *Escherichia coli*; *M. tuberculosis* = *Mycobacterium tuberculosis*; Mab = monoclonal antibody; the numbers following Mab identify the specific clone (see Methods and Materials).

Bacteria	Cardio-Lipin	Myosin	Actin	Coll I	Coll IV	Laminin	Fibro	B2AR	Creatine Kinase	Pyruvate Kinase
<i>S. aureus</i>	2 μ M	15 nM	>1 μ M	>1 μ M	22 nM	>1 μ M	6 nM	>1 μ M	500 nM	>10 μ M
GAS (<i>Rabbit</i>)	1 μ M	8 nM	>1 μ M	>1 μ M	>1 μ M	0.8 nM	>1 μ M	>1 μ M	300 nM	2 μ M

Table 6. Cont.

Bacteria	Cardio-Lipin	Myosin	Actin	Coll I	Coll IV	Laminin	Fibro	B2AR	Creatine Kinase	Pyruvate Kinase
<i>Strep (Goat)</i>	4 μ M	10 nM	>1 μ M	>1 μ M	>1 μ M	>1 μ M	--	>1 μ M	>10 μ M	>1 μ M
<i>GAS MAb 1-10698</i>	>100 μ M	0.2 nM	>1 μ M	4 nM	100 nM	2 nM	>1 μ M	--	>10 μ M	4 μ M
<i>GAS MAb 1-10700</i>	>100 μ M	3 nM	>1 μ M	>1 μ M	300 nM	>1 μ M	100 nM	--	>10 μ M	>10 μ M
<i>Klebsiella</i>	400 nM	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>10 μ M	>10 μ M
<i>E. coli</i>	1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>10 μ M	>1 μ M
<i>Clostridium</i>	>100 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	0.3 nM	>1 μ M		
<i>M. tuberculosis</i>	>100 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	>1 μ M	0.8 nM	>1 μ M	>10 μ M	2 μ M
<i>Enterococcus</i>	2 μ M	1.3 nM	>1 μ M	30 nM	>1 μ M	>1 μ M	--	--	>10 μ M	4 μ M




Figure 14. (Left) Results of quantitative ELISA experiments involving the binding of bacterial antibodies to the beta 2 adrenergic receptor (B2AR). *E. coli* = *Escherichia coli* antibody; *M. tuberculosis* = *Mycobacterium tuberculosis* antibody. SP = spike protein; SP1 = spike protein fragment 1; MP = Millipore; Inv = Invitrogen. (Right). Results of quantitative ELISA experiments involving the binding of microbial antibodies to cardiolipin. NP = nucleoprotein; SP1 = spike protein fragment 1; SP2 = spike protein fragment 2; RBG = spike protein RBG fragment; Env = envelope protein.




Figure 15. (Left) SARS-CoV-2 antibodies bind to Streptococcal (Strep), Staphylococcal (Staph), and Klebsiella (Kleb) antibodies. (Right) Enterococcus faecium antibodies binding to SARS-CoV-2, adenovirus, and coxsackievirus antibodies. SP1 = spike protein 1; SP2 = spike protein 2; NP = nucleoprotein; Envel = envelope protein.

	Myo- sin	Ac- tin	Tro- ponin	Lam- inin	Colla- gen	Connec- tin	Eno- loase	CK
Myosin					X			
Actin	B			X				
Troponin	B	B					X	
Laminin			B					
Collagen				B				
Connectin		B		B				
Enolase				B	B			
Creatine Kinase								
Pyruvate Kinase				B				B

Figure 16. Table summarizing known binding (B) (gray background) or antibody cross-reactivity (X) (white background) among the permutations of proteins studied here. CK = creatine kinase See the text for references.

2.6. Experimental Results of Virus Antibodies Binding to Bacterial Antibodies Using DA-ELISA

One of the unusual aspects of the previous results is that many of the targets of the virus and bacterial antibodies are cardiac proteins that are molecularly complementary to each other. For example, actin and myosin bind to form actinomyosin; the basement membrane of cardiomyocytes is formed by complexes of laminins and collagens; etc. The complementarity of the protein targets suggested that some of the antibodies cross-reacting with these proteins might also be complementary to each other, therefore acting like idiotype-anti-idiotype pairs. Double-antibody enzyme-linked immunoadsorption assays (DA-ELISAs) were used to explore this hypothesis, and a summary of the results is shown in Table 7.

Table 7. Summary of virus antibodies binding to bacterial antibodies by double-antibody ELISA. Pairs of antibodies that bind to each other with significant affinity are bolded for ease of identification. Entero. = *Enterococcus*; Strep. pneum. = *Streptococcus pneumoniae*; GAS = Group A *Streptococci*; Staph = *Staphylococcus aureus*; E. coli = *Escherichia coli*; Clost. = *Clostridium*; M. tb. = *Mycobacterium tuberculosis*; HRP = horse radish peroxidase-labeled antibody; Gt = goat antibody; Rab = rabbit antibody; Ms = mouse monoclonal antibody; S1 = SARS-CoV-2 spike protein S1 region; S2 = SARS-CoV-2 spike protein S2 region; RBD = SARS-CoV-2 spike protein RBD region; MP = Millipore; Inv = Invitrogen; CVB = coxsackievirus B1-B6; HSV = human herpes simplex virus; CMV = cytomegalovirus.

SARS-CoV-2	Entero. HRP	S. pneum. Gt HRP	GAS Rab HRP	Staph Gt HRP	Kleb Gt HRP	E. coli Gt HRP	Clost Rab HRP	M. tb GP
S1 (MP) Rab	250 nM	0.1 nM	1.7 nM	1 nM	>1 µM	>1 µM	>1 µM	NP
S2 (MP) Rab	3 nM	0.2 nM	1.8 nM	36 nM	0.2 nM	>1 µM	>1 µM	NP
RBD (MP) Rab	8 nM	0.4 nM	4.8 nM	>1 µM	>1 µM	>1 µM	>1 µM	NP
Envelope Rab	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	NP
Matrix Rab	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	NP
Nucleocapsid Rab	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	NP
OTHER VIRUSES								
Adenovirus Gt	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	NP	>1 µM	>1 µM
Influenza A Gt	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM	>1 µM
CVB blend Ms	--	0.2 nM	>1 µM	120 nM	>1 µM	0.3 nM	120 nM	>1 µM
CVB3 monkey	60 nM	500 nM	20 nM	10 nM	--	10 nM	1.5 nM	10 nM
HSV1 Gt	>1 µM	>1 µM	>1 µM	24 nM	>1 µM	>1 µM	>1 µM	>1 µM
HSV2 Gt	--	>1 µM	>1 µM	>1 µM	--	>1 µM	--	>1 µM
CMV Rab	--	>1 µM	>1 µM	>1 µM	--	>1 µM	--	70 nm

Figure 15 illustrates some of the resulting binding curves. These curves are generally not as well formed as those resulting from antibody binding to pure antigens (previous Figures) because these experiments universally employed polyclonal antibodies, in which a range of possible antibody-antibody specificities could theoretically exist. Thus, rather than a nice “S”-shaped curve, the curves resulting from polyclonal-antibody / polyclonal-antibody binding are often, as in Figure 15, slowly rising curves or display multiple levels of binding. Binding constants for such curves (Table 6) are therefore necessarily general estimates derived from the mid-points of these complex curves and are provided as general guides to the antibody-antibody affinities rather than as firm measures of specific affinity.

The results of the DA-ELISA experiments show that *Enterococcus*, *Streptococcus*, *Staphylococcus*, and *Klebsiella* bind with significant affinity to antibodies against spike protein antigens of SARS-CoV-2 but not to other SARS-CoV-2 proteins. This result is consistent with the spike protein, and these particular bacteria each display the majority of cardiac protein similarities. Notably, adenovirus antibodies did not bind to any of the bacterial antibodies, nor did influenza virus antibodies. Coxsackievirus antibodies, however, displayed an affinity for many of the bacterial antibodies, including several that the SARS-CoV-2 antibodies did not. Thus, viruses that are highly associated with autoimmune cardiopathies (SARS-CoV-2 and coxsackieviruses) produce antibodies that bind to bacteria associated with an unusually high risk of such cardiopathies (particularly *Streptococci*), while viruses unrelated to autoimmune cardiopathies seem to lack this property.

3. Discussion

3.1. Summary

The results of this study demonstrate that SARS-CoV-2 proteins mimic human cardiac proteins to a significantly greater degree than do other viruses such as Ad5, coxsackieviruses, or HCV that are associated with the risk of autoimmune cardiopathies, or influenza A H1N1 virus, which is not. Some antibodies against SARS-CoV-2 proteins, particularly those against elements of the spike protein, cross-react with some of these cardiac proteins, particularly myosin, actin, collagens, laminins, and the beta 2 adrenergic receptor. Adenovirus antibodies also recognized some cardiac proteins, including myosin, laminin, fibronectin, and beta 2 glycoprotein I. Additionally, coxsackievirus antibodies cross-reacted with myosin, actin, and collagen I, as previously reported [59,91]. The statistically significant increase in cardiac protein matches displayed by SARS-CoV-2 and Ad5 over PV, InfA, and HCV (Table 2) is similar to a previous study concerning similarities between these viruses and coagulopathy-related proteins [61,92]. Thus, SARS-CoV-2 increases the risk not only of autoimmune cardiopathies but also of autoimmune coagulopathies that can lead to cardiac arrest and stroke. The data concerning adenovirus is also of particular interest since Ad5 is used as a delivery vector for some SARS-CoV-2 spike protein vaccines under development (e.g., CanSino Biologics Inc. and Beijing Institute of Biotechnology, Ad5-nCoV; ImmunityBio, Inc. and NantKwest Inc., hAd5-S-Fusion+N-ETSD; Vaxart, VXA-COV2-1; Altimmune, Inc., AdCOVID), while other variants of adenoviruses are employed in the Janssen/Johnson and Johnson (Ad26.COV2-S; Human, Ad26) and the Oxford-AstraZeneca (ChAdOX1-nCoV; Chimpanzee, ChAdY25) [93]. It is likely that adenovirus vectors increase the probability of post-vaccinal autoimmune sequelae, and other virus vectors with lower risks, as determined by a combination of similarity and cross-reactivity studies, might be worthy of study.

The bacteria studied here, which were chosen for their frequency as co-infections with SARS-CoV-2 in hospitalized COVID-19 cases, also displayed a large number of similarities with cardiac proteins, many of which were confirmed by antibody cross-reactivity. Notably, the number of SARS-CoV-2 similarities to cardiac proteins pales in comparison with *Klebsiella pneumoniae* and is no greater than *Streptococcus pneumoniae* or *Enterococcus faecium* (Figure 1), suggesting that any of these bacteria could have at least as high a probability of inducing an autoimmune cardiopathy as the virus. However, the proportion that these similar antigens comprise within SARS-CoV-2 is far greater than among any bacterium

because SARS-CoV-2 is comprised of only thirteen proteins (and many COVID-19 vaccines, only the SARS-CoV-2 spike protein), while the average bacterium has thousands. Thus, the probability that the host immune system will preferentially respond to a SARS-CoV-2 antigen that mimics a heart protein is presumably much greater than the probability that it will respond to any particular bacterial antigen. The quality of the mimic, meaning the degree to which the protein mimics share some or all of their amino acid sequences, must also be a determinant of whether any particular mimic has the potential to induce autoimmunity. In this context, the very large number of very high-quality matches (an E value greater than or equal to 60) among SARS-CoV-2 and Streptococcal antigens as compared with the relatively few high-quality matches displayed by *E. faecium* may be an important factor to consider as determinants of autoimmune disease risk (Figure 2).

3.2. Comparison with Previous Study Results

The proteomic results presented here are similar to those found by other groups, although this study has used a different set of criteria for performing the searches and evaluating their significance. Previous studies have also identified a range of cardiac proteins, including tropomyosin and actin-binding proteins [94], ACE-2 and ANCA [95], and myosin [96,97], as potential targets of SARS-CoV-2 antibodies but not actin itself, collagens, laminins, adrenergic receptors, alpha enolase, or creatine or pyruvate kinases. Additionally, this is the first study to investigate whether bacterial infections associated with SARS-CoV-2 might also play a significant role in triggering cardiac autoimmunity in COVID-19.

As can be seen in Table 8, the existence of high-quality similarities, or their total number, between a microbe and cardiac proteins does not guarantee antibody cross-reactivity. Overall, the likelihood of inducing autoimmunity is presumably a function of at least three factors: the number of similar sequences a microbe displays, the proportion of antigens these similar sequences comprise, and the quality of the similarities. However, viruses with many high-quality matches do tend to induce polyclonal antibody responses that cross-react with the proteins to which they are most similar. In terms of sheer numbers, SARS-CoV-2 displays the most similarities to heart proteins of any virus tested and the most cross-reactivity with heart proteins exhibited by its antibodies. The same correlation is not as well observed among the bacteria, perhaps because, as noted above, the bacteria present a much larger number of antigens to the immune system, which must then target the most antigenic. It is also notable that while the sets of cardiac antigens that are recognized by the microbial antibodies overlap to some extent among the viruses and bacteria (e.g., myosin and collagens), the bacteria elicit a number of antibodies that cross-react with cardiac proteins that the viruses do not; these include cardiolipin, pyruvate kinase, fibronectin, and beta 2 glycoprotein I. Thus, the range of cardiac antigens targeted in any particular patient may depend on the virus, bacterium, or their combination.

Table 8. Summary of the proteomic similarity data and the ELISA results for the cardiac proteins in this study. The proteomic data are from Figure 2, where the formalism is explained. Boxes in orange are those for which significant microbial antibody binding was observed to the cardiac protein. White boxes are those for which no significant binding was observed. ND means that the proteomic search was not performed, so no prediction concerning binding was made. For cardiolipin, the negative signs (-) indicate no binding was observed; the plus signs (+) indicate that significant binding was observed. CoxB3 = coxsackievirus B3; InfA H1N1 = influenza virus H1N1; Strep. = Group A *Streptococci*; Staph. = *Staphylococcus*; Enter. = *Enterococcus*; Kleb. = *Klebsiella*.

	SARS-CoV-2 Spike Protein	SARS-CoV-2 Whole Virus	CoxB3	InfA H1N1	Adenovirus Type 5	Strep. pneum.	Staph. aureus	Enter. faecium	Kleb. pneum.
>6 of 10/6 of 10 E > 70/E > 60 < 70	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60	7/6 70/60
P13533 Cardiac myosin	1/0 0/0	3/11 1/6	1/13 0/2	0/0 0/0	3/7 1/4	7/28 35/0	3/10 1/3	0/13 1/2	18/25 2/7

Table 8. Cont.

	SARS-CoV-2 Spike Protein	SARS-CoV-2 Whole Virus	CoxB3	INF A H1N1	Adenovirus Type 5	<i>Strep.</i> <i>pneum.</i>	<i>Staph.</i> <i>aureus</i>	<i>Enter.</i> <i>faecium</i>	<i>Kleb.</i> <i>pneum.</i>
P68032 Cardiac actin	0/4 0/0	1/12 1/1	0/0 0/0	0/0 0/0	0/4 0/1	3/8 0/3	3/9 0/3	1/5 0/0	11/23 1/4
P02452 Collagen 1 alpha	1/1 0/1	2/6 0/4	3/5 0/0	0/0 0/0	0/0 0/0	2/2 1/0	1/3 0/0	1/5 0/0	6/14 1/3
P53420 Collagen IV	0/1 0/0	1/17 1/3	0/6 0/1	0/0 0/0	0/0 0/0	4/10 0/1	1/0 0/1	1/4 0/0	4/23 0/2
P25391 Laminin 1	1/7 0/1	3/27 0/7	1/7 0/4	0/0 0/0	1/6 0/2	0/4 1/2	4/7 1/3	7/31 0/3	9/17 0/3
P07550 Beta 2 ADR	0/4 0/1	3/12 1/3	0/2 0/0	0/0 0/0	2/5 0/2	2/8 0/2	1/6 0/2	1/8 0/1	4/16 0/4
P06732 Creatine Kinase	0/1 0/0	0/6 0/0	0/0 0/0	0/0 0/0	2/4 2/2	3/16 0/5	2/2 4/0	0/6 0/0	6/24 0/3
P14618 Pyruvate Kinase	0/0 0/0	1/5 0/0	0/1 0/0	0/0 0/0	0/0 0/0	4/17 0/7	15/0 15/0	1/12 0/0	6/23 1/5
P02749 β 2GPI	0/1 0/0	0/5 0/1	0/1 0/0	0/0 0/0	0/0 0/0	0/7 0/0	1/5 0/1	0/8 0/1	5/17 0/2
Cardiolipin	--	--	--	--	--	+	+	+	+
Fibronectin	ND	ND	ND	ND	ND	ND	ND	ND	ND

Similarities were found in the proteomic searches (Figure 1) and in the targets of autoimmunity observed in human patients (summarized in Table 9) that could not be tested for cross-reactivity here due to the limited availability of sufficient protein at affordable costs. These additional protein targets, which have been documented in both pre-COVID autoimmune cardiomyopathies and in COVID-19 autoimmune cardiopathies, included angiotensin converting enzyme 2 (ACE2) [51,98–100], antineutrophil cytoplasmic antibodies (ANCA) [101–103], alpha enolase [104], alpha- and beta-adrenergic receptors [42,105–109], laminins [110], phospholipids [111–113], tropomyosin [114], and troponin [104,115,116]. Table 9 summarizes the known autoantigens that are related to these cardiopathies in severe and hospitalized COVID-19 patients. Table 9 also summarizes and compares these clinical findings to our results and those of Vojdani et al.'s [117,118] testing of SARS-CoV-2-induced rabbit polyclonal antibodies and human monoclonal antibodies against cardiac-related proteins. There is a good correspondence between the human and rabbit results. This comparison demonstrates that antibody cross-reactivities fall into three groupings. One group involves cross-reactivities between SARS-CoV-2 antigens and human cardiac antigens that are not recognized by any of the anti-bacterial antibodies tested. The second group involves cross-reactivities to cardiac proteins by both SARS-CoV-2 and bacterial antibodies. And the third group consists of anti-bacterial antibodies against cardiac antigens that are not recognized by any of the SARS-CoV-2 antibodies tested (Table 9) [42,51,98–125]. The importance of these groupings is two-fold. First, it is evident that both SARS-CoV-2 and bacterial antigens can participate in inducing antibodies cross-reactive to cardiac autoantigens; and second, to account for the range of autoantigen targets observed in hospitalized COVID-19 patients, both SARS-CoV-2 and bacterial infections are required. For example, antibodies known to target actin, adrenergic receptors, phospholipids, and tropomyosin are induced by SARS-CoV-2 but not (as far as current studies indicate) by bacteria. On the other hand, no study has thus far reported that SARS-CoV-2 antibodies cross-react with β 2GPI, cardiolipin, alpha enolase, fibronectin, or pyruvate kinase, while all five of these proteins are known to be targets of bacterial antibodies. (Note that although alpha enolase was not tested for cross-reactivity in this study, numerous very high-quality proteomic similarities to bacterial enolases are reported here, and previous experimental studies [119–121] have reported cross-reactivity between these bacterial enolases and human enolases.) Finally, there are a number of cardiac proteins targeted by microbial antibodies, including collagens, creatine kinase, laminins, mitochondrial antigens, and myosin, that may be induced by either SARS-CoV-2 and/or bacterial antigens.

Table 9. Summary of studies comparing antibody reactivity to human cardiac proteins among autoimmune myocarditis (AM) and dilated cardiomyopathy (DM) pre-COVID-19 (condensed from Table 1); hospitalized and intensive care unit (ICU) admitted COVID-19 patients (condensed from Table 1); rabbit polyclonal and human monoclonal antibodies (Ab) against the SARS-CoV-2 spike protein (SP) or non-SP proteins; and the results of this study regarding SP, non-SP, and bacterial antibodies. The numbers in brackets refer to the References. Numbers followed by a percent sign (%) are the percent of patients in the group that displayed antibodies against that antibody. + signs indicate that antibodies are known to cross-react with that protein, but no data exists as to what percentage of patients exhibit these antibodies. The stars (*) indicate that while antibody tests were not carried out on enolase cross-reactivity in our study, our proteomic results demonstrate no significant similarities of enolase to SARS-CoV-2 proteins but very extensive and high-quality ones to all of the bacteria studied, and these have been independently verified for several of the bacteria [119–121]. Given the failure of any animal or human SARS-CoV-2 antibodies to cross-react with enolase, it is therefore conjectured that the source of these antibodies found in myocarditis patients must be bacterial. The carrot (ˆ) indicates that bacteria are known to induce anti-mitochondrial antibodies [122,123], and SARS-CoV-2 proteins are often produced using recombinant DNA techniques in *E. coli*, which has been demonstrated to result in contamination of the viral protein with bacterial antigens [124,125]; The possibility, therefore, must be considered that cross-reactivity to mitochondrial antigens by antibodies putatively induced by SARS-CoV-2 antigens is due to bacterial contaminants.

Antibody Target	Pre-COVID AM & DCM	Severe COVID-19 Hospitalized & ICU	Human Mab SARS-CoV-2 SP	Rabbit SARS-CoV-2 SP Ab	Rabbit SARS-CoV-2 SP Ab	Human Mab Non-SP SARS-CoV-2	Rabbit Non-SP SARS-CoV-2	Non-SP SARS-CoV-2 Abs	Poly-clonal Bacterial Abs
STUDIES [36–45]	[42,50,98–116]	[46–51,98–116]	[118]	[117,118]	This Study	[118]	[117,118]	This Study	This Study
Actin	71%	+	+	+	+	+	+	-	-
ACE2	+	3.8–27.2%							
ANCA	+	8.3–10.3%							
β2GPI	+	30.9–41.6%	-	-	-	-		-	+++
Adren. Rec.	30–75%	+			+			-	-
Cardiolipin	+	20.6%			-			-	+++++
Collagen	+	+	+	+	+	+	+	-	+++
CK	+	+			+			-	+
Enolase	+		-	-	-	-			***
Fibronectin	+	+	-	-	-	-		-	++++
Laminin	73–78%	+	-	-	+	-		-	++
Mitochondria	57–91%	+	+ ˆ	+ ˆ		+ ˆ			
Myosin	+	7.9%	+	+	+	-	+	+	++++
Phospholipids	+	7.9%	+	+		-	+		
PK	+	+			-			-	+++
Tropomyosin	55%	+	-	-		+	+		
Troponin 1	+	47.8%							
Cardiac Muscle	28–59%	27.8–68%							
Skeletal Muscle		19.4%							
Smooth Muscle		30.6%							

3.3. Evidence of Antigenic Complementarity between SARS-CoV-2 and Bacteria

To summarize thus far, proteomic similarity studies suggest that SARS-CoV-2 as well as bacteria associated with increased severity of COVID-19 both display unusual numbers of high-quality similarities to human cardiac proteins that in vitro and clinical studies generally confirm. One additional factor also implicates a combination of virus and bacteria in the induction of autoimmune cardiopathies, and that factor involves the

complementarity of the sets of SARS-CoV-2 and bacterial antibody targets described in Table 9. A majority of these protein targets are complementary to at least one of the others so that they bind to each other as part of their normal physiological function (Figure 16). Actin and myosin bind to each other to form actinomyosin [126], and these proteins can further bind troponin [127,128]. Troponin can also bind to laminin [129], as can alpha-enolase [130]. Indeed, an alternative name for bacterial enolases is “laminin binding protein” (e.g., Figure 8: UniProtKB, O69174.1) [131–133]. Alpha enolase can additionally bind strongly to fibronectin, fibrinogen, and collagen type IV [130] and is expressed on the cell surfaces of cardiomyocytes [134]. Laminins and collagens also bind to each other to form the extracellular matrix [135,136]. Connectin binds to both laminin and actin [137]. Pyruvate kinase binds to extracellular matrix proteins, including laminins and fibronectins [138]. And finally, creatine kinase and pyruvate kinase bind to each other [139–141] (Figure 17). Because of these overlapping affinities, some of these proteins are characterized by conserved binding regions, so that antibodies against myosin also recognize collagens [59,91,142]; antibodies against actin also recognize laminins [59,91], and antibodies against troponin also recognize alpha enolase [104] (Figure 16).

These binding complementarities are significant for two reasons in the context of autoimmune cardiopathies. First, just as SARS-CoV-2 utilizes the complementarity between its spike protein and ACE-2 to infect specific cell types, so the bacteria associated with COVID-19 utilize the complementarity between their extracellular protein antigens, such as enolase and pyruvate kinase, and extracellular matrix proteins, such as laminins, collagens, and fibronectins [143,144], on human tissues. Thus, some of the main targets of autoimmune cardiopathies are proteins such as ACE2 that mediate SARS-CoV-2 infection, while other targets are proteins mediating bacterial infections. Secondly, SARS-CoV-2 and adenoviruses mimic some cardiac proteins, while COVID-19-associated bacteria mimic complementary sets of proteins. Thus, combinations of viral and bacterial infections are highly likely to elicit antibodies that are complementary to each other, just as the inducing proteins are complementary to each other. This complementarity of microbial antigens and their human protein mimics likely explains the complementarity between SARS-CoV-2 antibodies and those from some of the bacteria that were observed in the DA-ELISA experiments above (Figures 17–19). The resulting idiotype-anti-idiotype relationship is actually the result of a pair of complementary idiotypic responses and may explain the observation that circulating immune complexes (CIC) are very frequent concomitants of autoimmune cardiopathies in general [145–148], including approximately 80% of severe cases of COVID-19 [149,150], the multisystem inflammatory syndrome in children (MIS-C) [151] and COVID-19 vaccine-related cardiopathies [152].

3.4. Proposed Model of Autoimmune Cardiopathy Induction

In short, the data aggregated here suggests that COVID-19 cardiopathies are induced in the following manner. SARS-CoV-2 and bacterial antigens cooperate to induce sets of antibodies that target complementary cardiac antigens and that act like idiotype-anti-idiotype pairs. Among the complementary sets of antigens known to bind to each other are actin and myosin, troponin and myosin, collagen and laminin, alpha enolase and laminin, pyruvate kinase, and collagen, etc. The virus utilizes ACE2 to infect tissues, while the bacteria utilize extracellular matrix proteins such as collagens, laminins, and fibronectin. A simplified cartoon of some of these relationships is provided in Figure 17.




Figure 17. Cartoon illustrating some key sets of complementary antigens and molecular mimics presented in COVID-19 autoimmune cardiopathies. SARS-CoV-2 and adenoviruses (“virus”) induce antibodies that are complementary to (in the sense of idiotype-anti-idiotype) antibodies against several bacteria that are common co- or super-infections of hospitalized COVID-19 patients, including Streptococci, Staphylococci, Klebsiella, and Enterococci (“Bacterium”). Collagen and laminin bind to each other to form the basement membrane of cardiomyocytes. Bacteria and viruses utilize laminin or collagen to bind to and infect cells. Actin and myosin bind to each other to form the active contractile element of muscles, actinomyosin. Data presented here and summarized from previous studies demonstrate that SARS-CoV-2 induces antibodies that also recognize collagen and actin. Bacteria induce antibodies that cross-react with laminin and myosin. Thus, significant complementarity and mimicry exist within the sets of antigens associated with cardiac complications present in hospitalized COVID-19 patients. The set of complementary antigens and antigen mimics illustrated here is not intended to be complete, and many additional examples are provided above, especially in Table 9.

The immune system responds to viral and bacterial infections by inducing two sets of antibodies, one against each type of microbe. Antibodies against the bacterium will cross-react with cardiac proteins such as laminins, fibronectin, and alpha enolase that mimic bacterial proteins. Antibodies against the virus will cross-react with cardiac proteins such as collagens, adrenergic receptors, or creatine kinases that mimic virus proteins. Because the autoantigens targeted by the virus and bacterial antibodies are themselves complementary and bind to each other, some of the antibodies against the virus and bacterium will also be complementary to each other, behaving like idiotype-anti-idiotype pairs to form CIC (Figure 18).




Figure 18. Cartoon illustrating the initiation of autoimmune cardiopathies. A virus that expresses antigens that mimic human cardiac proteins (SARS-CoV-2 and adenoviruses, in this case) elicits a set of antibodies (“antibody 2”). A bacterial co- or super-infection that mimics complementary cardiac proteins induces another set of antibodies (“antibody 1”). Some of these antibodies are complementary to each other (in the sense of idiotype-anti-idiotype) and bind to each other to form circulating immune complexes. The binding of viruses and bacteria to complementary antigens on cardiomyocytes results in the release of cardiac proteins, some of which are recognized by the microbe-induced antibodies because of molecular mimicry. The immune system is now unable to distinguish “self” from “non-self” because each microbe-induced antibody not only cross-reacts with a self-protein because of mimicry but also recognizes the other set of antibodies as targets as well.

Antibody binding to cell-surface antigens on cardiomyocytes, such as laminins, collagen, ACE2, adrenergic receptors, etc., as well as the presence of CIC, will initiate complement activation, resulting in destabilizing cardiomyocyte integrity. In consequence, cardiomyocytes will release previously hidden antigens such as actin, myosin, cardiolipin, and other mitochondrial antigens. These additional autoantigens also mimic some of the viral and bacterial antigens initiating the autoimmune response, provoking additional autoimmune activity and increased CIC production (Figure 19). It is likely that there is epitope drift in the antibody specificities due to the higher antigenicity of these hidden antigens.




Figure 19. Cartoon illustrating the second stage of the autoimmune attack on cardiomyocytes. Disruption of cardiomyocyte integrity by the attack on cross-reactive antigens such as collagen, laminin, adrenergic

adrenergic receptors (“b2AR”), or angiotensin converting enzyme 2 (“ACE2”) results in the release of so-called “hidden antigens” such as myosin and actin that become major targets of autoimmune disease due to epitope drift. The complementarity of these “self” antigens continues to drive the production of complementary antibodies, furthering the confusion between “self” and “non-self”.

Finally, it is important to realize that the antigen complementarity driving the antibody complementarity results in each antibody mimicking one of the antigens (Figure 20). Thus, the antibody against the bacterium may mimic a virus antigen, and the antibody against the virus may mimic a bacterial antigen. Additionally, each antibody will therefore mimic some of the host autoantigens as well. The overall result is to confuse the distinction between “self” and “non-self”. Since the specific heart proteins that each microbe mimics differ from one bacterium to another, these differences are likely to have consequences for the specific targets that are attacked should autoimmunity be induced, and thus the range of different symptoms that confuse the COVID-19 picture.




Figure 20. Cartoon illustrating some of the sets of antigen mimics that research has revealed are presented to the immune system in autoimmune cardiopathies. The virus presents antigens that mimic collagen and actin that elicit an antibody (“antibody 2”) that, in turn, mimics the complements of collagen and actin, which are laminin and myosin. The bacterium presents antigens that mimics, laminin and myosin, which results in another antibody (“antibody 1”) that mimics actin and collagen. Since the antigen sets are complementary, so are the antibodies. The result is total confusion about what is “self” and what is “non-self,” permitting autoimmune disease to progress. Note that the set of antigens listed here is not intended to be complete but merely illustrative. See the text for a discussion of additional sets of complementary sets of antigen mimics.

Additional consequences of targeting complementary antigens create an ongoing autoimmune disease process. The co-processing of complementary antigen complexes, such as laminin with collagen or myosin with actin, results in altered proteasome products that have higher autoimmunogenicity than occur when the same antigens are processed singly (reviewed in [153]). Virus antigens and bacterial antigens, and their host damage-associated molecular pattern (DAMP) mimics, each activate sets of toll-like receptors (TLR) and nucleotide-oligomer-domain-like receptors (NLR) that synergize to produce the hyper-inflammatory conditions that support or drive the autoimmunity; CIC can also drive innate activation (reviewed in [154,155]). Additionally, not only are complementary (idiotype-anti-idiotype) antibodies produced in response to complementary virus-bacterium infection, but complementary T cell receptors (TCR) also appear to be induced in COVID-19 autoimmune complications such as cardiopathies, coagulopathies, and MIS-C [156]. Moreover, these

TCR pairs, because they mimic complementary antigens, each mimic one of the antigens, so that the immune system becomes complicit in driving ongoing autoimmunity [156]. Thus, induction of complementary sets of antibodies (and TCR) by complementary sets of antigens that cross-react with complementary sets of autoantigens creates all of the conditions within the innate and adaptive immune systems necessary to overcome “self” tolerance and to support an ongoing autoimmune disease process [52,53,157–160].

The model is generalizable. We have previously demonstrated that SARS-CoV-2 can interact with some of the bacteria studied here to provoke autoimmune coagulopathies directed against blood proteins [61,92] and a similar approach might illuminate the causes of other autoimmune complications associated with SARS-CoV-2 infections. The basic hypothesis is that different strains of SARS-CoV-2 combined with different bacterial co- or super-infections are likely to trigger different types of autoimmunity depending on the particular sets of complementary antigens the microbes display in common with their host. It is additionally likely that the risk of any particular type of autoimmune complication is partially determined by host genetic variations, as has been found for all other autoimmune diseases. Additionally, a very similar model has independently been proposed to explain the etiology of anti-neutrophil cytoplasm antibody (ANCA) vasculitis as a result of the immune response to proteinase 3, collagen, and their complementary antigens, which include plasminogen [161–166]. Thus, vascular autoimmunity following COVID-19 may be induced by a mechanism similar to the one described here.

The model describing the induction of autoimmune cardiopathies in COVID-19 applies equally to understanding the rare instances of such cardiopathies following SARS-CoV-2 vaccination, other COVID-19 autoimmune complications, and autoimmune cardiopathies that occur in conjunction with other virus and bacterial infections. Given the large number of high-quality similarities between the SARS-CoV-2 spike protein that is present in all current COVID-19 vaccines, it is evident that the simple presence of molecular mimicry is not sufficient to induce autoimmunity since the vast majority of infected and vaccinated people do not develop such complications. The extraordinary rarity of such complications argues instead for the necessity of some type of cofactor: for example, a complementary bacterial infection coinciding with the vaccination period. Since most people receiving vaccinations are healthy, the incidence of such complementary bacterial infections (as opposed to any microbial infection whatever) can be assumed to be extremely low. However, one implication of the present study is that it may be possible to decrease the risk even further by screening people who are to receive vaccines for fever and the presence of *Staphylococcal*, *Streptococcal*, *Klebsiella*, and *Enterococcus* bacterial infections, whether oropharyngeal, respiratory, nasal, gastrointestinal, urogenital or involving the skin. Additionally, vaccination against streptococcal infections by means of pneumococcal vaccines has been demonstrated in numerous studies to lower the risk of hospitalization and death during the COVID-19 pandemic [167–176] and may do so, at least in part, by decreasing the risk of autoimmune complications.

Our data are also important for revealing significant risks for autoimmune cardiopathies associated with adenoviruses and coxsackieviruses (Figure 19). The risks of autoimmune cardiopathies associated with both viruses have been documented previously (coxsackieviruses [52,53,59,91,177–179]; adenoviruses [177–179], but, as with SARS-CoV-2, the proportion of affected individuals is extremely small compared with the numbers of people infected. The model proposed above may, again, provide a possible explanation: these viruses may need the presence of appropriate bacterial co- or super-infections to transform their molecular mimicry of cardiac proteins into an unregulated attack on “self”. This proposition has previously been examined in the case of coxsackievirus-associated autoimmune myocarditis, which is highly associated in some studies with concurrent infections of coxsackieviruses and group A *Streptococci* (e.g., [180–185]; and reviewed in [59,91]. The possibility that other bacteria may synergize with other cardiotropic viruses such as adenoviruses has not, apparently, been examined. and can stand as a prediction made by the model presented here. The possible role of adenoviruses in promoting the increased risk of such autoimmune complications as either co-infections of SARS-CoV-2 or

as vectors for SARS-CoV-2 vaccines is clearly warranted given the greater proportion of vaccinees who develop cardiopathies following adenovirus-vectored vaccines than those receiving nanoparticle-delivered vaccines [22–24].

3.5. Limitations

This study has a number of limitations. One is that it has used non-human antibodies that may or may not reflect the range of specificity of human polyclonal antibodies. On the other hand, Table 9 demonstrates that the results reported here do correlate well with the results of clinical studies and previous studies of cross-reactivity using human monoclonal antibodies [118]. A second limitation is the limited range of cardiac proteins that were tested for cross-reactivity. ACE2, alpha-enolase, and troponin are among the particularly important proteins that warrant further investigation as targets of autoimmunity observed in clinical studies, but the expense of these proteins created a barrier to the investigation here. Mitochondrial antigens were also ignored in this study but represent a target in autoimmune cardiopathies identified in both clinical and in vitro studies (Figure 20). A third limitation of this study is the lack of an animal model to test the hypothesis that autoimmune disease is induced by combinations of viral and bacterial antigens. Notably, however, two groups have previously demonstrated that coxsackieviruses combined with streptococcal antigens do induce autoimmune cardiopathies in rodents [181,186], and *Klebsiella* antigens have been successfully used in combination with heart proteins to induce autoimmune myocarditis in mice [187], which makes the prediction that SARS-CoV-2 antigens in combination with these bacteria will do the same.

3.6. Further Tests

Many of the implications of our data can be tested further in animal models. For example, SARS-CoV-2-susceptible species (such as golden hamsters or some strains of mice) might be co-infected with the virus and with bacteria such as group A Streptococci, Staphylococci, *Klebsiella*, or Enterococci, and in combination with adenoviruses. The effect of such bacterial coinfections on vaccination with SARS-CoV-2 vaccines could be tested similarly. Our prediction is that animals infected with only SARS-CoV-2 or its vaccine or with the bacterium alone will not develop cardiopathies, while coinfecting animals will demonstrate increased rates of cardiopathies. Alternatively, since it is assumed here that COVID-19 coagulopathies are autoimmune diseases, it should be possible to inoculate naive rabbits with combinations of polyclonal (rabbit) antibodies against the SARS-CoV-2 proteins (e.g., spike, nucleoprotein, or whole virus) in combination with (rabbit) polyclonal antibodies against group A Streptococci, Staphylococci, Enterococci, etc. Such combinations are predicted to produce clinically evident cardiopathies. Correspondingly, we predict that rabbits inoculated with only the SARS-CoV-2 antibodies or only the bacterial antibodies will not develop cardiopathies.

Further clinical studies are also needed. Are people who have been recently vaccinated against pneumococci less likely than those who are unvaccinated or who have not been vaccinated since childhood to develop autoimmune cardiomyopathies following COVID-19? Do people who develop such autoimmune cardiomyopathies have evidence of one or more of the bacterial infections identified here as complementary inducers of autoimmunity? Are hospitalized COVID-19 patients who are treated with broad-spectrum antibiotics at admission less likely to develop autoimmune complications than those who are so treated later in their disease course or those who are not given antibiotics (see, e.g., [187])? Do broadly acting inhibitors such as melatonin (reviewed in [44,154,155]) and steroids [188,189] that work simultaneously against multiple innate receptors to moderate the hyperinflammation that accompanies COVID-19 also lower the risk of autoimmune complications? Much remains to be known.

4. Materials and Methods

4.1. Similarity Searches

Two types of similarity searches were carried out to identify likely molecular mimics shared by SARS-CoV-2 proteins (accessed on 2 May 2021 from <https://viralzone.expasy.org/8996>) and human myocardial proteins (sequences accessed 2 May 2021 from UniProtKB <https://www.uniprot.org/help/uniprotkb>). The first type of search utilized BLASTP (version 2.2.31+) on the www.expasy.org server. BLOSUM80 was used to identify the type of short, continuous sequences approximately ten to fifteen amino acids in length that are presented by human leukocyte antigens (HLA) to T and B cells [47,48]. The E value was set to 1; filter low-complexity regions on; no gaps; 3000 best scoring and best alignments to show. Only matches that had a Waterman-Eggert score of at least 50, an E value of less than 1.0, and contained a sequence of ten amino acids in which at least six were identical were counted as sufficiently similar to induce possible cross-reactive immunity; this criterion is based on substantial research demonstrating that sequences exhibiting at least this degree of similarity have a >85% probability of being cross-reactive under experimental conditions [58–61].

The second search method employed LALIGN (www.expasy.org, accessed on 17 February 2022–14 May 2023) to do a deeper dive into the SARS-CoV-2 protein (accessed on 2 May 2021 from <https://viralzone.expasy.org/8996>) and identify similarities identified by the BLAST searches. The search algorithm was set to BLOSUM80, with a gap penalty of −10.0 and an E value of 10. The 20 best matches were displayed. The control viruses were poliovirus type 1, coxsackievirus B3, hepatitis A virus, rhinovirus 2, adenovirus 5, and influenza virus H1N1 (Wilson). UniProt accession numbers for the viruses and for the human myocardial proteins, as well as a list of the blood proteins, are provided in the table captions. As with the BLAST searches and for the same reasons, the LALIGN results were further culled for sequences with $E < 1$, Waterman-Eggert score > 45 , and sequence similarity having a region containing at least six out of ten identities. The number of matches simultaneously satisfying the E value, Waterman-Eggert, and 6-of-10 criteria was tabulated, and representative matches were provided. We note that LALIGN on the Expasy server was decommissioned after we had completed this study. We find that running protein BLAST on the NCBI server https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome (accessed on 7 July 2023) with the following settings yields very similar results but without providing Waterman-Eggert scores: BLOSUM80. $E = 100$, word size 3, existence 8; extension −2; eliminate low-complexity regions.

Cardiolipin could not be searched using either BLAST or LALIGN since it is not a protein, but its presence in each bacterium was determined from existing experimental literature [190,191].

4.2. Statistics

Statistics were applied to the tabulated LALIGN results using a paired T-test to explore pairwise comparisons between each class of virus-human protein combination and every other (<https://www.graphpad.com/quickcalcs/ttest2/> (accessed on 7 July 2023)). Since all possible permutations of the results were explored, a Bonferroni correction was applied to the resulting p values (<https://www.easycalculation.com/statistics/bonferroni-correction-calculator.php> (accessed on 7 July 2023)). To satisfy $p = 0.05$ after a Bonferroni correction for the 10 pairwise comparisons made between the various viruses, the uncorrected p value had to be < 0.005 ($T > 3.0$) to satisfy $p = 0.05$.

4.3. Experimental Protocols

ELISA and double-antibody ELISA (DA-ELISA) were employed to investigate whether the similarity searches yielded immunologically valuable information.

An enzyme-linked immunosorbent assay (ELISA) was used to investigate cross-reactivities between microbial antibodies and cardiac tissue-related proteins. The tissue protein was diluted in pH 7.4 phosphate buffer to a concentration of 10 μM . This standard

solution was then diluted by ten-fold steps to about 10–14 M. Two wells received only phosphate buffer as controls. 100 μ L of each protein dilution was added in duplicate to the wells of a Costar round-bottomed 96-well ELISA plate and incubated for one hour. The excess protein was triple washed out using a 1% Tween 20 solution (in phosphate buffer) and a plate washer. Next, 200 μ L of blocking agent (2% polyvinylalcohol in phosphate buffer) was added to every well, incubated for an hour, and then triply washed. An antibody against a microbe (at 1 mg/mL concentration) was then diluted to 1/200 in phosphate buffer and 100 μ L added to every well. The antibody was incubated for an hour and then triply washed. A species-appropriate horseradish peroxidase-linked secondary antibody was then diluted to 1/1000, incubated for an hour, and triply washed. Finally, 100 μ L of ABTS reagent (Chemicon) was added, and incubated for 30 min, and the plate read at 405 nm in a Spectramax UV-VIS scanning spectrophotometer. The data were gathered using Spectramax software (version 4.0) and then analyzed using Excel. Analysis essentially consisted of subtracting non-specific binding to the buffer-only wells from the protein-containing wells and plotting the amount of antibody binding (as measured by absorbance at 405 nm) as a function of protein concentration.

Double antibody ELISA (DA-ELISA) was used to investigate possible antigenic complementarity between the antibodies used in the study. DA-ELISA differs from ELISA in that the protein laid down in the 96-well plate in the initial step of an ELISA is substituted with an antibody. A second antibody (from a different species) is tested for its ability to bind to the first. The ability of the second antibody to bind to the first is then monitored using peroxidase-linked antibodies against the species from which the second antibody is derived [90,91]. As in the ELISA protocol, the first antibody is made up at a concentration of about 10 μ M (assuming IgG antibodies have a molecular weight of 180,000 daltons) and then serially diluted by factors of ten. The rest of the protocol is the same.

4.4. Antigens

A list of the antigens utilized in experiments is provided in Table 10. The choice of antigens was determined by two factors: (1) whether the antigen is a known target of autoantibodies in COVID-19 cardiomyopathies (see Introduction, Table 1), and (2) the cost of the antigen. Given the large number of quantitative ELISA binding studies performed, some proteins known to be targets of autoantibodies in COVID-19 cardiomyopathies were too expensive for our budget (e.g., angiotensin II receptor; tropomyosin). Where possible and economically feasible, human proteins were utilized.

Table 10. List of antigens utilized in experiments. # = number.

Product Name	Species	Supplier	Product #	Purity
Actin, alpha cardiac	Human	Hypermol	8201-02	>99%
Actin from bovine muscle	Cow	Sigma-Aldrich	A3653	>90%
Actin from rabbit muscle	Rabbit	Sigma-Aldrich	A2522	>85%
Cardiolipin from heart	Cow	Sigma-Aldrich	C0563	>97%
Collagen Type I from placenta	Human	Sigma-Aldrich	C7774	>95%
Collagen Type IV from placenta	Human	Sigma-Aldrich	C7521	>95%
Collagen Type IV	Mouse	Cultrex	3410-010-01	>99%
Creatine Kinase (cardiac MM)	Human	Sigma-Aldrich	C9858-100UN	>1000 U/mg
Fibronectin from plasma	Human	Cultrex	3420-001-01	>99%
Fibronectin from plasma	Human	Sigma-Aldrich	F2006	>85%
Laminin from fibroblasts	Human	Sigma-Aldrich	L4544	>90%

Table 10. Cont.

Product Name	Species	Supplier	Product #	Purity
Laminin-1	Mouse	Cultrex	3400-010-01	>99%
Myosin light chain, cardiac	Human	Sigma-Aldrich	M4824	>90%
Myosin Ca ²⁺ Activated, cardiac	Pig	Sigma-Aldrich	M0531	0.5 U/mg
Pyruvate Kinase (recombinant)	Human	Sigma-Aldrich	SAE0021	>100 U/μg

4.5. Antibodies

A list of the antibodies used in experiments is provided in Table 11. The choice of antibodies was determined by several factors: (1) polyclonality (autoimmune diseases result from polyclonal antibody activation, not monoclonal specificity); (2) availability (e.g., polyclonal antibodies against SARS-CoV-2 replicase protein could not be located); and (3) (especially for use in DA-ELISA experiments where different host species are needed unless one is an HRP-conjugated version—see Section 4.3 above), the host species.

Table 11. List of antibodies utilized in experiments. # = number.

Product Name	Species	Supplier	Product #
Actin antibody	Rabbit	Sigma-Aldrich	A2668
Adenovirus	Goat	Millipore	AB1056
<i>Clostridia</i>	Rabbit	Invitrogen	PA1-7210
<i>Clostridium</i> sp. HRP	Rabbit	US Biological	C5853-25C
Collagen IV	Rabbit	Novus Biologicals	NB120-6586
Coxsackie Virus B1-B6 Blend	Mouse	Millipore	MAB9410
<i>Enterococcus</i> HRP	Rabbit	Invitrogen	PA1-73122
<i>Escherichia coli</i>	Goat	abcam	AB13627
Goat Anti-Mouse IgG HRP	Goat	Sigma-Aldrich	A9917
Goat Anti-Rabbit IgG HRP	Goat	Invitrogen	65-6120
Herpes Simplex Virus Type 1	Goat	Invitrogen	PA1-7493
Influenza A HRP	Goat	Biodesign International	B65243G
<i>Klebsiella pneumoniae</i> HRP	Rabbit	Invitrogen	PA1-73176
Laminin antibody	Rabbit	Sigma-Aldrich	L9393
<i>Mycobacterium tuberculosis</i>	Rabbit	ABD Serotec	OBT0947
<i>Mycobacterium tuberculosis</i>	Guinea Pig	MyBioSource	MBS315001
Myosin antibody	Goat	Santa Cruz Biotechnology	12117
Rabbit Anti-Goat IgG HRP	Rabbit	Millipore	AP106P
Rabbit Anti-Guinea Pig HRP	Rabbit	abcam	AB6771
SARS-CoV-2 Envelope protein	Rabbit	Invitrogen	PA1-41158
SARS-CoV-2 Matrix protein	Rabbit	Invitrogen	PA1-41160
SARS-CoV-2 Nucleocapsid	Rabbit	Invitrogen	PA5-116894
SARS-CoV-2 Spike Protein RBD	Rabbit	Millipore	ABF1064
SARS-CoV-2 Spike Protein S1	Rabbit	Millipore	ABF1065
SARS-CoV-2 Spike Protein S1	Rabbit	Invitrogen	PA5-116916
SARS-CoV-2 Spike Protein S2	Rabbit	Millipore	ABF1063

Table 11. Cont.

Product Name	Species	Supplier	Product #
<i>Staphylococcus aureus</i>	Rabbit	Invitrogen	PA1-7246
<i>Staphylococcus aureus</i> HRP	Rabbit	Invitrogen	PA1-73173
<i>Streptococcus</i> Group A	Goat	Invitrogen	PA1-7249
<i>Streptococcus</i> Group A HRP	Rabbit	Acris Antibodies	BP2026HRP
<i>Streptococcus pneumoniae</i>	Rabbit	Biodesign International	B65831R
<i>Streptococcus pneumoniae</i>	Rabbit	Invitrogen	PA1-7259

5. Conclusions

The evidence compiled here strongly suggests that autoimmune cardiopathies following COVID-19 occur mainly in severe cases associated with bacterial co- or super-infections. SARS-CoV-2 itself mimics some of the known cardiac proteins targeted in such autoimmune cardiopathies, while bacteria such as Streptococci, Staphylococci, Klebsiella, and Enterococci mimic an overlapping but largely complementary set of cardiac proteins. Combinations of SARS-CoV-2 with various bacteria therefore result in the production of complementary sets of antibodies that not only cross-react with sets of complementary proteins such as collagens, laminins, and fibronectins, or myosins, actins, and troponins, but also with each other to form idiotype-anti-idiotype immune complexes. The result of this complex set of mimics and complements is the activation of complementary immune responses that lose the ability to distinguish “self” from “non-self”. The complementarity of the antigens, as well as the production of immune complexes, further drives an ongoing hyperactivation of the innate immune system.

The implications of these findings have practical value. One is that vaccination against bacterial co- or super-infections in COVID-19 should substantially decrease the risk of autoimmune cardiopathies, as should the timely and appropriate use of antibiotics for high-risk individuals. A second is that the risk of post-vaccinal cardiopathies may similarly be decreased in people recently vaccinated against pneumococci and screened for potentially complementary bacterial infections at the time of vaccination. A third is that it may be possible to implement new animal models of autoimmune cardiopathies employing combinations of viruses such as SARS-CoV-2, adenoviruses, or coxsackieviruses in combination with appropriate complementary bacteria such as Streptococci, Staphylococci, or Enterococci. Such models might permit novel treatments to be developed.

Author Contributions: Study conception, R.R.-B.; project oversight, R.R.-B.; methods, R.R.-B.; data acquisition, J.H., M.P. and A.Z.; data analysis, R.R.-B., J.H., M.P. and A.Z.; data visualization, R.R.-B., J.H., M.P. and A.Z.; paper draft, R.R.-B.; paper editing, R.R.-B., J.H., M.P. and A.Z.; resource acquisition, R.R.-B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data not already provided in the manuscript can be obtained by contacting the primary investigator (RRB: rootbern@msu.edu).

Conflicts of Interest: The authors declare no conflict of interest.

References

- Novelli, L.; Motta, F.; De Santis, M.; Ansari, A.A.; Gershwin, M.E.; Selmi, C. The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19—A systematic review of the literature. *J. Autoimmun.* **2021**, *117*, 102592. [\[CrossRef\]](#)
- Talotta, R.; Robertson, E. Autoimmunity as the comet tail of COVID-19 pandemic. *World J. Clin. Cases* **2020**, *8*, 3621–3644. [\[CrossRef\]](#)

3. Dotan, A.; Muller, S.; Kanduc, D.; David, P.; Halpert, G.; Shoenfeld, Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. *Autoimmun. Rev.* **2021**, *20*, 102792. [\[CrossRef\]](#)
4. Vahabi, M.; Ghazanfari, T.; Sepehrnia, S. Molecular mimicry, hyperactive immune system, and SARS-CoV-2 are three prerequisites of the autoimmune disease triangle following COVID-19 infection. *Int. Immunopharmacol.* **2022**, *112*, 109183. [\[CrossRef\]](#)
5. Morgan, M.C.; Atri, L.; Harrell, S.; Al-Jaroudi, W.; Berman, A. COVID-19 vaccine-associated myocarditis. *World J. Cardiol.* **2022**, *14*, 382–391. [\[CrossRef\]](#)
6. Dhaduk, K.; Khosla, J.; Hussain, M.; Mangaroliya, V.; Chauhan, S.; Ashish, K.; Gupta, R.; Pal, S. COVID-19 vaccination and myocarditis: A review of current literature. *World J. Virol.* **2022**, *11*, 170–175. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Power, J.R.; Keyt, L.K.; Adler, E.D. Myocarditis following COVID-19 vaccination: Incidence, mechanisms, and clinical considerations. *Expert Rev. Cardiovasc. Ther.* **2022**, *20*, 241–251. [\[CrossRef\]](#) [\[PubMed\]](#)
8. Bozkurt, B.; Kamat, I.; Hotez, P.J. Myocarditis with COVID-19 mRNA Vaccines. *Circulation* **2021**, *144*, 471–484. [\[CrossRef\]](#)
9. Mitrani, R.D.; Dabas, N.; Goldberger, J.J. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. *Heart Rhythm.* **2020**, *17*, 1984–1990. [\[CrossRef\]](#)
10. Sandoval, Y.; Januzzi, J.L., Jr.; Jaffe, A.S. Cardiac Troponin for Assessment of Myocardial Injury in COVID-19: JACC Review Topic of the Week. *J. Am. Coll. Cardiol.* **2020**, *76*, 1244–1258. [\[CrossRef\]](#)
11. Manolis, A.S.; Manolis, T.A.; Manolis, A.A.; Melita, H. Cardiovascular implications and complications of the coronavirus disease-2019 pandemic: A world upside down. *Curr. Opin. Cardiol.* **2021**, *36*, 241–251. [\[CrossRef\]](#)
12. Shchendrygina, A.; Nagel, E.; Puntmann, V.O.; Valbuena-Lopez, S. COVID-19 myocarditis and prospective heart failure burden. *Expert Rev. Cardiovasc. Ther.* **2021**, *19*, 5–14. [\[CrossRef\]](#) [\[PubMed\]](#)
13. Jeantin, L.; Picjereau, C.; Pineton de Chambrun, M. Myocarditis, paraparesia and ARDS associated to COVID-19 infection. *Heart Lung* **2021**, *50*, 6–8. [\[CrossRef\]](#)
14. An, W.; Kang, J.S.; Wang, Q.; Kim, T.E. Cardiac biomarkers and COVID-19: A systematic review and meta-analysis. *J. Infect. Public Health* **2021**, *14*, 1191–1197. [\[CrossRef\]](#) [\[PubMed\]](#)
15. Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. *JAMA Cardiol.* **2020**, *5*, 802–810. [\[CrossRef\]](#)
16. Toubiana, J.; Poirault, C.; Corsia, A.; Bajolle, F.; Fourgeaud, J.; Angoulvant, F.; Debray, A.; Basmaci, R.; Salvador, E.; Biscardi, S.; et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: Prospective observational study. *BMJ* **2020**, *369*, m2094. [\[CrossRef\]](#) [\[PubMed\]](#)
17. Ho, J.S.; Sia, C.H.; Chan, M.Y.; Lin, W.; Wong, R.C. Coronavirus-induced myocarditis: A meta-summary of cases. *Heart Lung* **2020**, *49*, 681–685. [\[CrossRef\]](#)
18. Haslbauer, J.D.; Tzankov, A.; Mertz, K.D.; Schwab, N.; Nienhold, R.; Twerenbold, R.; Leibundgut, G.; Stalder, A.K.; Matter, M.; Glatz, K. Characterisation of cardiac pathology in 23 autopsies of lethal COVID-19. *J. Pathol. Clin. Res.* **2021**, *7*, 326–337. [\[CrossRef\]](#)
19. Barda, N.; Dagan, N.; Ben-Shlomo, Y.; Kepten, E.; Waxman, J.; Ohana, R.; Hernán, M.A.; Lipsitch, M.; Kohane, I.; Netzer, D.; et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N. Engl. J. Med.* **2021**, *385*, 1078–1090. [\[CrossRef\]](#)
20. Montgomery, J.; Ryan, M.; Engler, R.; Hoffman, D.; McClenathan, B.; Collins, L.; Loran, D.; Hrcir, D.; Herring, K.; Platzer, M.; et al. Myocarditis Following Immunization with mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol.* **2021**, *6*, e212833. [\[CrossRef\]](#)
21. Hendren, N.S.; Carter, S.; Grodin, J.L. Severe COVID-19 vaccine associated myocarditis: Zebra or unicorn? *Int. J. Cardiol.* **2021**, *343*, 197–198. [\[CrossRef\]](#)
22. Levin, D.; Shimon, G.; Fadlon-Derai, M.; Gershovitz, L.; Shovali, A.; Sebbag, A.; Bader, S.; Fink, N.; Gordon, B. Myocarditis following COVID-19 vaccination—A case series. *Vaccine* **2021**, *39*, 6195–6200. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Franczuk, P.; Tkaczyszyn, M.; Kulak, M.; Domenico, E.; Ponikowski, P.; Jankowska, E.A. Cardiovascular Complications of Viral Respiratory Infections and COVID-19. *Biomedicines* **2022**, *11*, 71. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Heidecker, B.; Dagan, N.; Balicer, R.; Eriksson, U.; Rosano, G.; Coats, A.; Tschöpe, C.; Kelle, S.; Poland, G.A.; Frustaci, A.; et al. Myocarditis following COVID-19 vaccine: Incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on Myocardial and Pericardial Diseases. *Eur. J. Heart Fail.* **2022**, *24*, 2000–2018. [\[CrossRef\]](#)
25. Smith, A.P.; Williams, E.P.; Plunkett, T.R.; Selvaraj, M.; Lane, L.C.; Zalduondo, L.; Xue, Y.; Vogel, P.; Channappanavar, R.; Jonsson, C.B.; et al. Time-dependent increase in susceptibility and severity of secondary bacterial infections during SARS-CoV-2. *Front. Immunol.* **2022**, *13*, 894534. [\[CrossRef\]](#)
26. Barman, T.K.; Singh, A.K.; Bonin, J.L.; Nafiz, T.N.; Salmon, S.L.; Metzger, D.W. Lethal synergy between SARS-CoV-2 and *Streptococcus pneumoniae* in hACE2 mice and protective efficacy of vaccination. *JCI Insight* **2022**, *7*, e159422. [\[CrossRef\]](#)
27. Moreno-García, E.; Puerta-Alcalde, P.; Letona, L.; Meira, F.; Dueñas, G.; Chumbita, M.; Garcia-Pouton, N.; Monzó, P.; Lopera, C.; Serra, L.; et al. Bacterial co-infection at hospital admission in patients with COVID-19. *Int. J. Infect. Dis.* **2022**, *118*, 197–202. [\[CrossRef\]](#)
28. Garcia-Vidal, C.; Sanjuan, G.; Moreno-García, E.; Puerta-Alcalde, P.; Garcia-Pouton, N.; Chumbita, M.; Fernandez-Pittol, M.; Pitart, C.; Inciarte, A.; Bodro, M.; et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: A retrospective cohort study. *Clin. Microbiol. Infect.* **2021**, *27*, 83–88. [\[CrossRef\]](#)

29. Said, K.B.; Alsolami, A.; Moussa, S.; Alfouzan, F.; Bashir, A.I.; Rashidi, M.; Aborans, R.; Taha, T.E.; Almansour, H.; Alazmi, M.; et al. COVID-19 clinical profiles and fatality rates in hospitalized patients reveal case aggravation and selective co-infection by limited gram-negative bacteria. *Int. J. Environ. Res. Public Health* **2022**, *19*, 5270. [\[CrossRef\]](#)
30. Rawson, T.M.; Moore, L.S.P.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. *Clin. Infect. Dis.* **2020**, *71*, 2459–2468. [\[CrossRef\]](#)
31. Sreenath, K.; Batra, P.; Vinayaraj, E.V.; Bhatia, R.; SaiKiran, K.; Singh, V.; Singh, S.; Verma, N.; Singh, U.B.; Mohan, A.; et al. Coinfections with Other Respiratory Pathogens among Patients with COVID-19. *Microbiol. Spectr.* **2021**, *9*, e0016321. [\[CrossRef\]](#)
32. Lai, C.C.; Wang, C.Y.; Hsueh, P.R. Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? *J. Microbiol. Immunol. Infect.* **2020**, *53*, 505–512. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Iversen, K.; Ihlemann, N.; Gill, S.U.; Madsen, T.; Elming, H.; Jensen, K.T.; Bruun, N.E.; Høfsten, D.E.; Fursted, K.; Christensen, J.J.; et al. Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis. *N. Engl. J. Med.* **2019**, *380*, 415–424. [\[CrossRef\]](#)
34. Ramos-Martínez, A.; Fernández-Cruz, A.; Domínguez, F.; Forteza, A.; Cobo, M.; Sánchez-Romero, I.; Asensio, A. Hospital-acquired infective endocarditis during Covid-19 pandemic. *Infect. Prev. Pract.* **2020**, *2*, 100080. [\[CrossRef\]](#) [\[PubMed\]](#)
35. Quintero-Martínez, J.A.; Hindy, J.R.; Mahmood, M.; Gerberi, D.J.; DeSimone, D.C.; Baddour, L.M. A clinical profile of infective endocarditis in patients with recent COVID-19: A systematic review. *Am. J. Med. Sci.* **2022**, *364*, 16–22. [\[CrossRef\]](#)
36. Liu, Y.; Fang, L.; Chen, W.; Zhu, Y.; Lin, X.; Wang, Y.; Li, X.; Wang, Q.; Liu, Z. Identification of characteristics of overt myocarditis in adult patients with idiopathic inflammatory myopathies. *Cardiovasc. Diagn. Ther.* **2020**, *10*, 405–420. [\[CrossRef\]](#) [\[PubMed\]](#)
37. Kallel, O.; Bourouis, I.; Bougrine, R.; Housni, B.; El Ouafi, N.; Ismaili, N. Acute myocarditis related to COVID-19 infection: 2 cases report. *Ann. Med. Surg.* **2021**, *66*, 102431. [\[CrossRef\]](#)
38. Linschoten, M.; Peters, S.; van Smeden, M.; Jewbali, L.S.; Schaap, J.; Siebelink, H.M.; Smits, P.C.; Tieleman, R.G.; van der Harst, P.; van Gilst, W.H.; et al. CAPACITY-COVID collaborative consortium. Cardiac complications in patients hospitalised with COVID-19. *Eur. Heart J. Acute Cardiovasc. Care* **2020**, *9*, 817–823. [\[CrossRef\]](#)
39. Li, C.; Chen, Y.; Zhao, Y.; Lung, D.C.; Ye, Z.; Song, W.; Liu, F.F.; Cai, J.P.; Wong, W.M.; Yip, C.C.; et al. Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model. *Clin. Infect. Dis.* **2021**, *74*, 1933–1950. [\[CrossRef\]](#)
40. Shmilovich, H.; Danon, A.; Binah, O.; Roth, A.; Chen, G.; Wexler, D.; Keren, G.; George, J. Autoantibodies to cardiac troponin I in patients with idiopathic dilated and ischemic cardiomyopathy. *Int. J. Cardiol.* **2007**, *117*, 198–203. [\[CrossRef\]](#)
41. Pankuweit, S.; Portig, I.; Lottspeich, F.; Maisch, B. Autoantibodies in sera of patients with myocarditis: Characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis. *J. Mol. Cell. Cardiol.* **1997**, *29*, 77–84. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Caforio, A.L.; Tona, F.; Bottaro, S.; Vinci, A.; Dequal, G.; Daliento, L.; Thiene, G.; Illiceto, S. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. *Autoimmunity* **2008**, *41*, 35–45. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Dao, T.L.; Hoang, V.T.; Gautret, P. Recurrence of SARS-CoV-2 viral RNA in recovered COVID-19 patients: A narrative review. *Eur. J. Clin. Microbiol. Infect. Dis.* **2021**, *40*, 13–25. [\[CrossRef\]](#)
44. Root-Bernstein, R. Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions. *Int. J. Mol. Sci.* **2020**, *21*, 4645. [\[CrossRef\]](#)
45. Wu, Y.; Qin, Y.H.; Liu, Y.; Zhu, L.; Zhao, X.X.; Liu, Y.Y.; Luo, S.W.; Tang, G.S.; Shen, Q. Cardiac troponin I autoantibody induces myocardial dysfunction by PTEN signaling activation. *EBioMedicine* **2019**, *47*, 329–340. [\[CrossRef\]](#)
46. Chang, S.E.; Feng, W.; Meng, W. Apostolidis SA. New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19. *medRxiv* **2021**. [\[CrossRef\]](#)
47. Richter, A.G.; Shields, A.M.; Karim, A.; Birch, D.; Faustini, S.E.; Steadman, L.; Ward, K.; Plant, T.; Reynolds, G.; Veenith, T.; et al. Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. *Clin. Exp. Immunol.* **2021**, *205*, 99–105. [\[CrossRef\]](#)
48. Shi, H.; Zuo, Y.; Gandhi, A.A.; Sule, G.; Yalavarthi, S.; Gockman, K.; Madison, J.A.; Wang, J.; Zuo, M.; Shi, Y.; et al. Endothelial cell-activating antibodies in COVID-19. *medRxiv* **2021**. medRxiv:2021.01.18.21250041. [\[CrossRef\]](#)
49. Vlachoyiannopoulos, P.G.; Magira, E.; Alexopoulos, H.; Jahaj, E.; Theophilopoulou, K.; Kotanidou, A.; Tzioufas, A.G. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. *Ann. Rheum. Dis.* **2020**, *79*, 1661–1663. [\[CrossRef\]](#)
50. Fagyas, M.; Nagy, B., Jr.; Ráduly, A.P.; Mányiné, I.S.; Mártha, L.; Erdősi, G.; Sipka, S., Jr.; Enyedi, E.; Szabó, A.Á.; Pólik, Z.; et al. The majority of severe COVID-19 patients develop anti-cardiac autoantibodies. *GeroScience* **2022**, *44*, 2347–2360. [\[CrossRef\]](#)
51. Casciola-Rosen, L.; Thiemann, D.R.; Andrade, F.; Trejo-Zambrano, M.I.; Leonard, E.K.; Spangler, J.B.; Skinner, N.E.; Bailey, J.; Yegnasubramanian, S.; Wang, R.; et al. IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. *JCI Insight* **2022**, *7*, e158362. [\[CrossRef\]](#)
52. Root-Bernstein, R.; Fairweather, D. Unresolved issues in theories of autoimmune disease using myocarditis as a framework. *J. Theor. Biol.* **2015**, *375*, 101–123. [\[CrossRef\]](#)
53. Root-Bernstein, R.; Fairweather, D. Complexities in the relationship between infection and autoimmunity. *Curr. Allergy Asthma Rep.* **2014**, *14*, 407. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Cunningham, M.W. Molecular Mimicry, Autoimmunity, and Infection: The Cross-Reactive Antigens of Group A Streptococci and their Sequelae. *Microbiol. Spectr.* **2019**, *7*. [\[CrossRef\]](#)

55. Massilamany, C.; Huber, S.A.; Cunningham, M.W.; Reddy, J. Relevance of molecular mimicry in the mediation of infectious myocarditis. *J. Cardiovasc. Transl. Res.* **2014**, *7*, 165–171. [\[CrossRef\]](#)
56. Rudensky, Y.; Preston-Hurlburt, P.; Hong, S.C.; Barlow, A.; Janeway, C.A., Jr. Sequence analysis of peptides bound to MHC class II molecules. *Nature* **1991**, *353*, 622–627. [\[CrossRef\]](#)
57. Suri, A.; Lovitch, S.B.; Unanue, E.R. The wide diversity and complexity of peptides bound to class II MHC molecules. *Curr. Opin. Immunol.* **2006**, *18*, 70–77. [\[CrossRef\]](#)
58. Cunningham, M.W.; McCormack, J.M.; Fenderson, P.G.; Ho, M.K.; Beachey, E.H.; Dale, J.B. Human and murine antibodies cross-reactive with streptococcal M protein and myosin recognize the sequence GLN-LYS-SER-LYS-GLN in M protein. *J. Immunol.* **1989**, *143*, 2677–2683. [\[CrossRef\]](#)
59. Root-Bernstein, R.; Vonck, J.; Podufaly, A. Antigenic complementarity between coxsackie virus and streptococcus in the induction of rheumatic heart disease and autoimmune myocarditis. *Autoimmunity* **2009**, *42*, 1–16. [\[CrossRef\]](#)
60. Root-Bernstein, R. Human Immunodeficiency Virus Proteins Mimic Human T Cell Receptors Inducing Cross-Reactive Antibodies. *Int. J. Mol. Sci.* **2017**, *18*, 2091. [\[CrossRef\]](#)
61. Root-Bernstein, R.; Huber, J.; Ziehl, A. Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies. *Int. J. Mol. Sci.* **2022**, *23*, 11500. [\[CrossRef\]](#)
62. Waterman, M.S.; Eggert, M. A new algorithm for best subsequence alignments with application to tRNA-rRNA comparisons. *J. Mol. Biol.* **1987**, *197*, 723–728. [\[CrossRef\]](#)
63. Tschöpe, C.; Ammirati, E.; Bozkurt, B.; Caforio, A.L.P.; Cooper, L.T.; Felix, S.B.; Hare, J.M.; Heidecker, B.; Heymans, S.; Hübner, N.; et al. Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. *Nature reviews. Cardiology* **2021**, *18*, 169–193. [\[CrossRef\]](#)
64. Rose, N.R. Viral myocarditis. *Curr. Opin. Rheumatol.* **2016**, *28*, 383–389. [\[CrossRef\]](#)
65. Myers, J.M.; Fairweather, D.; Huber, S.A.; Cunningham, M.W. Autoimmune myocarditis, valvulitis, and cardiomyopathy. *Curr. Protoc. Immunol.* **2013**, *15*, 15.14.1–15.14.51. [\[CrossRef\]](#)
66. Figulla, H.R. Transformation of myocarditis and inflammatory cardiomyopathy to idiopathic dilated cardiomyopathy: Facts and fiction. *Med. Microbiol. Immunol.* **2004**, *193*, 61–64. [\[CrossRef\]](#)
67. Frustaci, A.; Pieroni, M.; Chimenti, C. Immunosuppressive treatment of chronic non-viral myocarditis. *Ernst Scher. Res. Found. Workshop* **2006**, *55*, 343–351. [\[CrossRef\]](#)
68. Pankuweit, S.; Hufnagel, G.; Eckhardt, H.; Herrmann, H.; Uttecht, S.; Maisch, B. Kardiotrope DNA-Viren und Bakterien in der Pathogenese der dilatativen Kardiomyopathie mit und ohne Entzündung [Cardiotropic DNA viruses and bacteria in the pathogenesis of dilated cardiomyopathy with or without inflammation]. *Med. Klin.* **1998**, *93*, 223–228. [\[CrossRef\]](#)
69. Kaplan, M.H. Rheumatic fever, rheumatic heart disease, and the streptococcal connection: The role of streptococcal antigens cross-reactive with heart tissue. *Rev. Infect. Dis.* **1979**, *1*, 988–996. [\[CrossRef\]](#)
70. Guilherme, L.; Faé, K.C.; Oshiro, S.E.; Tanaka, A.C.; Pomerantzeff, P.M.; Kalil, J. T cell response in rheumatic fever: Crossreactivity between streptococcal M protein peptides and heart tissue proteins. *Curr. Protein Pept. Sci.* **2007**, *8*, 39–44. [\[CrossRef\]](#)
71. Cunningham, M.W. Streptococcus and rheumatic fever. *Curr. Opin. Rheumatol.* **2012**, *24*, 408–416. [\[CrossRef\]](#) [\[PubMed\]](#)
72. Cunningham, M.W. Rheumatic fever, autoimmunity, and molecular mimicry: The streptococcal connection. *Int. Rev. Immunol.* **2014**, *33*, 314–329. [\[CrossRef\]](#) [\[PubMed\]](#)
73. Cunningham, M.W.; Antone, S.M.; Gulizia, J.M.; McManus, B.M.; Fischetti, V.A.; Gauntt, C.J. Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 1320–1324. [\[CrossRef\]](#)
74. Massilamany, C.; Koenig, A.; Reddy, J.; Huber, S.; Buskiewicz, I. Autoimmunity in picornavirus infections. *Curr. Opin. Virol.* **2016**, *16*, 8–14. [\[CrossRef\]](#)
75. Feng, J.J.; Ushakov, D.S.; Ferenczi, M.A.; Laing, N.G.; Nowak, K.J.; Marston, S.B. Direct visualisation and kinetic analysis of normal and nemaline myopathy actin polymerisation using total internal reflection microscopy. *J. Muscle Res. Cell Motil.* **2009**, *30*, 85–92. [\[CrossRef\]](#)
76. Delforge, J.; Mesangeau, D.; Dolle, F.; Merlet, P.; Loc'h, C.; Bottlaender, M.; Trebossen, R.; Syrota, A. In vivo quantification and parametric images of the cardiac beta-adrenergic receptor density. *J. Nucl. Med. Off. Publ. Soc. Nucl. Med.* **2002**, *43*, 215–226.
77. Deguchi, H.; Fernandez, J.A.; Hackeng, T.M.; Banka, C.L.; Griffin, J.H. Cardiolipin is a normal component of human plasma lipoproteins. *Proc. Natl. Acad. Sci. USA* **2000**, *97*, 1743–1748. [\[CrossRef\]](#)
78. Barceló-Coblijn, G.; Collison, L.W.; Jolly, C.A.; Murphy, E.J. Dietary alpha-linolenic acid increases brain but not heart and liver docosahexaenoic acid levels. *Lipids* **2005**, *40*, 787–798. [\[CrossRef\]](#)
79. Grover-McKay, M.; Scholz, T.D.; Burns, T.L.; Skorton, D.J. Myocardial collagen concentration and nuclear magnetic resonance relaxation times in the spontaneously hypertensive rat. *Investig. Radiol.* **1991**, *26*, 227–232. [\[CrossRef\]](#)
80. de Souza, R.R. Aging of myocardial collagen. *Biogerontology* **2002**, *3*, 325–335. [\[CrossRef\]](#)
81. Alzahri, M.S. The Utility of Serum Creatinine Kinase in Emergency Department Patients with Possible Substance-use Related Conditions. *West. J. Emerg. Med.* **2020**, *21*, 1195–1200. [\[CrossRef\]](#) [\[PubMed\]](#)
82. Yagi, K.; Mase, R. Coupled reaction of creatine kinase and myosin A-adenosine triphosphatase. *J. Biol. Chem.* **1962**, *237*, 397–403. [\[CrossRef\]](#) [\[PubMed\]](#)

83. Zerlauth, G.; Wolf, G. Plasma fibronectin as a marker for cancer and other diseases. *Am. J. Med.* **1984**, *77*, 685–689. [[CrossRef](#)] [[PubMed](#)]
84. Silva, A.C.; Pereira, C.; Fonseca, A.C.R.G.; Pinto-do-Ó, P.; Nascimento, D.S. Bearing My Heart: The Role of Extracellular Matrix on Cardiac Development, Homeostasis, and Injury Response. *Front. Cell Dev. Biol.* **2021**, *8*, 621644. [[CrossRef](#)] [[PubMed](#)]
85. Lumkwana, D.; Botha, A.; Samodien, E.; Hanser, S.; Lopes, J. Laminin, laminin-entactin and extracellular matrix are equally appropriate adhesive substrates for isolated adult rat cardiomyocyte culture and experimentation. *Cell Adhes. Migr.* **2018**, *12*, 503–511. [[CrossRef](#)]
86. Iwamura, C.; Hirahara, K.; Kiuchi, M.; Ikehara, S.; Azuma, K.; Shimada, T.; Kuriyama, S.; Ohki, S.; Yamamoto, E.; Inaba, Y.; et al. Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2-induced lung exudative vasculitis and predicts COVID-19 severity. *Proc. Natl. Acad. Sci. USA* **2022**, *119*, e2203437119. [[CrossRef](#)]
87. Dobson, G.P.; Hitchins, S.; Teague, W.E., Jr. Thermodynamics of the pyruvate kinase reaction and the reversal of glycolysis in heart and skeletal muscle. *J. Biol. Chem.* **2002**, *277*, 27176–27182. [[CrossRef](#)]
88. McDowell, G.; Gupta, S.; Dellerba, M.; Coppinger, T.; Levy, R.D.; Keevil, B.G. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure. *Ann. Clin. Biochem.* **2004**, *41 Pt 6*, 491–493. [[CrossRef](#)]
89. Lind, S.E.; Smith, D.B.; Janmey, P.A.; Stossel, T.P. Depression of gelsolin levels and detection of gelsolin-actin complexes in plasma of patients with acute lung injury. *Am. Rev. Respir. Dis.* **1988**, *138*, 429–434. [[CrossRef](#)]
90. Lee, P.S.; Patel, S.R.; Christiani, D.C.; Bajwa, E.; Stossel, T.P.; Waxman, A.B. Plasma gelsolin depletion and circulating actin in sepsis: A pilot study. *PLoS ONE* **2008**, *3*, e3712. [[CrossRef](#)]
91. Root-Bernstein, R. Rethinking Molecular Mimicry in Rheumatic Heart Disease and Autoimmune Myocarditis: Laminin, Collagen IV, CAR, and B1AR as Initial Targets of Disease. *Front. Pediatr.* **2014**, *2*, 85. [[CrossRef](#)] [[PubMed](#)]
92. Root-Bernstein, R. COVID-19 coagulopathies: Human blood proteins mimic SARS-CoV-2 virus, vaccine proteins and bacterial co-infections inducing autoimmunity: Combinations of bacteria and SARS-CoV-2 synergize to induce autoantibodies targeting cardiolipin, cardiolipin-binding proteins, platelet factor 4, prothrombin, and coagulation factors. *BioEssays News Rev. Mol. Cell. Dev. Biol.* **2021**, *43*, e2100158. [[CrossRef](#)]
93. Mendonça, S.A.; Lorincz, R.; Boucher, P.; Curiel, D.T. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. *npj Vaccines* **2021**, *6*, 97. [[CrossRef](#)] [[PubMed](#)]
94. Nunez-Castilla, J.; Stebliankin, V.; Baral, P.; Balbin, C.A.; Sobhan, M.; Cickovski, T.; Mondal, A.M.; Narasimhan, G.; Chapagain, P.; Mathee, K.; et al. Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins. *Viruses* **2022**, *14*, 1415. [[CrossRef](#)] [[PubMed](#)]
95. Damoiseaux, J.; Dotan, A.; Fritzler, M.J.; Bogdanos, D.P.; Meroni, P.L.; Roggenbuck, D.; Goldman, M.; Landegren, N.; Bastard, P.; Shoenfeld, Y.; et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. *Autoimmun. Rev.* **2022**, *21*, 103012. [[CrossRef](#)]
96. Kanduc, D. From Anti-SARS-CoV-2 Immune Response to the Cytokine Storm via Molecular Mimicry. *Antibodies* **2021**, *10*, 36. [[CrossRef](#)]
97. Kanduc, D. From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecular Mimicry. *Antibodies* **2020**, *9*, 33. [[CrossRef](#)]
98. Arthur, J.M.; Forrest, J.C.; Boehme, K.W.; Kennedy, J.L.; Owens, S.; Herzog, C.; Liu, J.; Harville, T.O. Development of ACE2 autoantibodies after SARS-CoV-2 infection. *PLoS ONE* **2021**, *16*, e0257016. [[CrossRef](#)]
99. Rodriguez-Perez, A.I.; Labandeira, C.M.; Pedrosa, M.A.; Valenzuela, R.; Suarez-Quintanilla, J.A.; Cortes-Ayaso, M.; Mayán-Conesa, P.; Labandeira-Garcia, J.L. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. *J. Autoimmun.* **2021**, *122*, 102683. [[CrossRef](#)]
100. Lai, Y.C.; Cheng, Y.W.; Chao, C.H.; Chang, Y.Y.; Chen, C.D.; Tsai, W.J.; Wang, S.; Lin, Y.S.; Chang, C.P.; Chuang, W.J.; et al. Antigenic Cross-Reactivity between SARS-CoV-2 S1-RBD and Its Receptor ACE2. *Front. Immunol.* **2022**, *13*, 868724. [[CrossRef](#)]
101. Gori, T. Coronary Vasculitis. *Biomedicines* **2021**, *9*, 622. [[CrossRef](#)] [[PubMed](#)]
102. Fireizen, Y.; Shahriary, C.; Imperial, M.E.; Randhawa, I.; Nianiaris, N.; Ovunc, B. Pediatric P-ANCA vasculitis following COVID-19. *Pediatr. Pulmonol.* **2021**, *56*, 3422–3424. [[CrossRef](#)] [[PubMed](#)]
103. Batu, E.D.; Sener, S.; Ozen, S. COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis. *Semin. Arthritis Rheum.* **2022**, *55*, 152047. [[CrossRef](#)] [[PubMed](#)]
104. Okazaki, T.; Honjo, T. Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. *Trends Mol. Med.* **2005**, *11*, 322–326. [[CrossRef](#)] [[PubMed](#)]
105. Cabral-Marques, O.; Halpert, G.; Schimke, L.F.; Ostrinski, Y.; Vojdani, A.; Baiocchi, G.C.; Freire, P.P.; Filgueiras, I.S.; Zyskind, I.; Lattin, M.T.; et al. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity. *Nat. Commun.* **2022**, *13*, 1220. [[CrossRef](#)]
106. Seidel, F.; Scheibenbogen, C.; Heidecke, H.; Opgen-Rhein, B.; Pickardt, T.; Klingel, K.; Berger, F.; Messroghli, D.; Schubert, S. Compensatory Upregulation of Anti-Beta-Adrenergic Receptor Antibody Levels Might Prevent Heart Failure Presentation in Pediatric Myocarditis. *Front. Pediatr.* **2022**, *10*, 881208. [[CrossRef](#)]
107. Leiros, C.P.; Sterin-Borda, L.; Borda, E. Beta-adrenergic cardiac antibody in autoimmune myocarditis. *Autoimmunity* **1989**, *2*, 223–234. [[CrossRef](#)]
108. Caforio, A.L.; Mahon, N.J.; Tona, F.; McKenna, W.J. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: Pathogenetic and clinical significance. *Eur. J. Heart Fail.* **2002**, *4*, 411–417. [[CrossRef](#)]

109. Wallukat, G.; Hohberger, B.; Wenzel, K.; Fürst, J.; Schulze-Rothe, S.; Wallukat, A.; Hönigke, A.S.; Müller, J. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. *J. Transl. Autoimmun.* **2021**, *4*, 100100. [\[CrossRef\]](#)
110. Galvin, J.E.; Hemric, M.E.; Ward, K.; Cunningham, M.W. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. *J. Clin. Investig.* **2000**, *106*, 217–224. [\[CrossRef\]](#)
111. Djokovic, A.; Stojanovich, L.; Kontic, M.; Stanisavljevic, N.; Radovanovic, S.; Marisavljevic, D. Association between cardiac manifestations and antiphospholipid antibody type and level in a cohort of Serbian patients with primary and secondary antiphospholipid syndrome. *Isr. Med. Assoc. J.* **2014**, *16*, 162–167. [\[PubMed\]](#)
112. Tung, M.L.; Tan, B.; Cherian, R.; Chandra, B. Anti-phospholipid syndrome and COVID-19 thrombosis: Connecting the dots. *Rheumatol. Adv. Pract.* **2021**, *5*, rkaa081. [\[CrossRef\]](#) [\[PubMed\]](#)
113. Gil-Etayo, F.J.; Garcinuño, S.; Lalueza, A.; Díaz-Simón, R.; García-Reyne, A.; Pleguezuelo, D.E.; Cabrera-Marante, O.; Rodriguez-Frias, E.A.; Perez-Rivilla, A.; Serrano, M.; et al. Anti-Phospholipid Antibodies and COVID-19 Thrombosis: A Co-Star, Not a Supporting Actor. *Biomedicines* **2021**, *9*, 899. [\[CrossRef\]](#) [\[PubMed\]](#)
114. Zhang, Y.; Zhao, H.; Liu, B.; Li, L.; Zhang, L.; Bao, M.; Ji, X.; He, X.; Yi, J.; Chen, P.; et al. Low Level Antibodies Against Alpha-Tropomyosin Are Associated with Increased Risk of Coronary Heart Disease. *Front. Pharmacol.* **2020**, *11*, 195. [\[CrossRef\]](#)
115. Salbach, C.; Kaya, Z. Cardiac Troponin I autoantibodies and their potential role in cardiac remodelling. *EBioMedicine* **2019**, *48*, 11–12. [\[CrossRef\]](#)
116. Jahns, R. Autoantibodies against cardiac troponin I: Friend or foe? *Eur. J. Heart Fail.* **2010**, *12*, 645–648. [\[CrossRef\]](#)
117. Vojdani, A.; Kharrazian, D. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases. *Clin. Immunol.* **2020**, *217*, 108480. [\[CrossRef\]](#)
118. Vojdani, A.; Vojdani, E.; Kharrazian, D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins with Tissue Antigens: Implications for Autoimmune Diseases. *Front. Immunol.* **2021**, *11*, 617089. [\[CrossRef\]](#)
119. Fontán, P.A.; Pancholi, V.; Nociari, M.M.; Fischetti, V.A. Antibodies to streptococcal surface enolase react with human alpha-enolase: Implications in poststreptococcal sequelae. *J. Infect. Dis.* **2000**, *182*, 1712–1721. [\[CrossRef\]](#)
120. Dobrut, A.; Brzywczy-Włoch, M. Immunogenic Proteins of Group B Streptococcus-Potential Antigens in Immunodiagnostic Assay for GBS Detection. *Pathogens* **2021**, *11*, 43. [\[CrossRef\]](#)
121. Carneiro, C.R.; Postol, E.; Nomizo, R.; Reis, L.F.; Brentani, R.R. Identification of enolase as a laminin-binding protein on the surface of Staphylococcus aureus. *Microbes Infect.* **2004**, *6*, 604–608. [\[CrossRef\]](#) [\[PubMed\]](#)
122. Chowdhury, A.; Witte, S.; Aich, A. Role of Mitochondrial Nucleic Acid Sensing Pathways in Health and Patho-Physiology. *Front. Cell Dev. Biol.* **2022**, *10*, 796066. [\[CrossRef\]](#)
123. Zhang, Q.; Raoof, M.; Chen, Y.; Sumi, Y.; Sursal, T.; Junger, W.; Brohi, K.; Itagaki, K.; Hauser, C.J. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* **2010**, *464*, 104–107. [\[CrossRef\]](#) [\[PubMed\]](#)
124. Cinquegrani, G.; Spigoni, V.; Iannozzi, N.T.; Parello, V.; Bonadonna, R.C.; Dei Cas, A. SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: Endotoxin contamination and lack of protein glycosylation as possible confounders. *Cell Biol. Toxicol.* **2022**, *38*, 667–678. [\[CrossRef\]](#)
125. Ouyang, W.; Xie, T.; Fang, H.; Gao, C.; Stantchev, T.; Clouse, K.A.; Yuan, K.; Ju, T.; Frucht, D.M. Variable Induction of Pro-Inflammatory Cytokines by Commercial SARS CoV-2 Spike Protein Reagents: Potential Impacts of LPS on In Vitro Modeling and Pathogenic Mechanisms In Vivo. *Int. J. Mol. Sci.* **2021**, *22*, 7540. [\[CrossRef\]](#)
126. Krans, J.L. The Sliding Filament Theory of Muscle Contraction. *Nat. Educ.* **2010**, *3*, 66.
127. Schoffstall, B.; LaBarbera, V.A.; Brunet, N.M.; Gavino, B.J.; Herring, L.; Heshmati, S.; Kraft, B.H.; Inchausti, V.; Meyer, N.L.; Moonoo, D.; et al. Interaction between troponin and myosin enhances contractile activity of myosin in cardiac muscle. *DNA Cell Biol.* **2011**, *30*, 653–659. [\[CrossRef\]](#)
128. Solís, C.; Robinson, J.M. Cardiac troponin and tropomyosin bind to F-actin cooperatively, as revealed by fluorescence microscopy. *FEBS Open Bio* **2020**, *10*, 1362–1372. [\[CrossRef\]](#)
129. Suzuki, H.; Arakawa, Y.; Ito, M.; Yamada, H.; Horiguchi-Yamada, J. Cloning of a newly identified heart-specific troponin I isoform, which lacks the troponin T binding portion, using the yeast hybrid system. *Exp. Clin. Cardiol.* **2006**, *11*, 4–7.
130. Hussain, M.; Kohler, C.; Becker, K. Enolase of Staphylococcus lugdunensis Is a Surface-Exposed Moonlighting Protein That Binds to Extracellular Matrix and the Plasminogen/Plasmin System. *Front. Microbiol.* **2022**, *13*, 837297. [\[CrossRef\]](#)
131. Wang, X.; Wang, C.; Wu, M.; Tian, T.; Cheng, T.; Zhang, X.; Zang, J. Enolase binds to RnpA in competition with PNPase in Staphylococcus aureus. *FEBS Lett.* **2017**, *591*, 3523–3535. [\[CrossRef\]](#) [\[PubMed\]](#)
132. Lopes, J.D.; Da-Mota, G.F.; Carneiro, C.R.; Gomes, L.; Costa-e-Silva-Filho, F.; Brentani, R.R. Evolutionary conservation of laminin-binding proteins. *Braz. J. Med. Biol. Res.* **1988**, *21*, 1269–1273. [\[PubMed\]](#)
133. Santos, M.G.C.; Trindade, C.N.D.R.; Vommario, R.C.; Domingues, R.M.C.P.; Ferreira, E.O. Binding of the extracellular matrix laminin-1 to Clostridioides difficile strains. *Mem. Inst. Oswaldo Cruz* **2022**, *117*, e220035. [\[CrossRef\]](#) [\[PubMed\]](#)
134. Díaz-Ramos, A.; Roig-Borrellas, A.; García-Melero, A.; López-Aleman, R. α -Enolase, a multifunctional protein: Its role on pathophysiological situations. *J. Biomed. Biotechnol.* **2012**, *2012*, 156795. [\[CrossRef\]](#)
135. Charonis, A.S.; Tsilibary, E.C.; Yurchenco, P.D.; Furthmayr, H. Binding of laminin to type IV collagen: A morphological study. *J. Cell Biol.* **1985**, *100*, 1848–1853. [\[CrossRef\]](#)

136. Sato-Nishiuchi, R.; Li, S.; Ebisu, F.; Sekiguchi, K. Recombinant laminin fragments endowed with collagen-binding activity: A tool for conferring laminin-like cell-adhesive activity to collagen matrices. *Matrix Biol. J. Int. Soc. Matrix Biol.* **2018**, *65*, 75–90. [\[CrossRef\]](#)
137. Brown, S.S.; Malinoff, H.L.; Wicha, M.S. Connectin: Cell surface protein that binds both laminin and actin. *Proc. Natl. Acad. Sci. USA* **1983**, *80*, 5927–5930. [\[CrossRef\]](#)
138. Gründel, A.; Jacobs, E.; Dumke, R. Interactions of surface-displayed glycolytic enzymes of *Mycoplasma pneumoniae* with components of the human extracellular matrix. *Int. J. Med. Microbiol. IJMM* **2016**, *306*, 675–685. [\[CrossRef\]](#)
139. Sears, P.R.; Dillon, P.F. Differential coupling of smooth and skeletal muscle pyruvate kinase to creatine kinase. *Biochemistry* **1999**, *38*, 14881–14886. [\[CrossRef\]](#)
140. Dillon, P.F.; Clark, J.F. The theory of diazymes and functional coupling of pyruvate kinase and creatine kinase. *J. Theor. Biol.* **1990**, *143*, 275–284. [\[CrossRef\]](#)
141. Kraft, T.; Hornemann, T.; Stolz, M.; Nier, V.; Wallimann, T. Coupling of creatine kinase to glycolytic enzymes at the sarcomeric I-band of skeletal muscle: A biochemical study in situ. *J. Muscle Res. Cell Motil.* **2000**, *21*, 691–703. [\[CrossRef\]](#)
142. Tandon, R.; Sharma, M.; Chandrashekar, Y.; Kotb, M.; Yacoub, M.H.; Narula, J. Revisiting the pathogenesis of rheumatic fever and carditis. *Nat. Rev. Cardiol.* **2013**, *10*, 171–177. [\[CrossRef\]](#)
143. Singh, B.; Fleury, C.; Jalalvand, F.; Riesbeck, K. Human pathogens utilize host extracellular matrix proteins laminin and collagen for adhesion and invasion of the host. *FEMS Microbiol. Rev.* **2012**, *36*, 1122–1180. [\[CrossRef\]](#) [\[PubMed\]](#)
144. Chagnot, C.; Listrat, A.; Astruc, T.; Desvaux, M. Bacterial adhesion to animal tissues: Protein determinants for recognition of extracellular matrix components. *Cell. Microbiol.* **2012**, *14*, 1687–1696. [\[CrossRef\]](#) [\[PubMed\]](#)
145. Ilyas, S.Z.; Tabassum, R.; Hamed, H.; Rehman, S.U.; Qadri, I. Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity. *Viral Immunol.* **2017**, *30*, 633–641. [\[CrossRef\]](#) [\[PubMed\]](#)
146. Fairweather, D.; Frisancho-Kiss, S.; Njoku, D.B.; Nyland, J.F.; Kaya, Z.; Yung, S.A.; Davis, S.E.; Frisancho, J.A.; Barrett, M.A.; Rose, N.R. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1 β , and immune complex deposition in the heart. *J. Immunol.* **2006**, *176*, 3516–3524. [\[CrossRef\]](#)
147. Maisch, B.; Drude, L.; Kochsiek, K. Immunological features in a case of hypereosinophilic syndrome and myocarditis. *Heart Vessel.* **1990**, *5*, 237–242. [\[CrossRef\]](#)
148. Maisch, B.; Kochsiek, K. Gumoral'nyi i kletochnyi immunitet pri perimiokardite i zastoĭnoi kardiomiopatii [Humoral and cellular immunity in perimyocarditis and congestive cardiomyopathy]. *Kardiologiya* **1985**, *25*, 95–102.
149. Ankerhold, J.; Giese, S.; Kolb, P.; Maul-Pavicic, A.; Voll, R.E.; Göppert, N.; Cimini, K.; Kreutz, C.; Lothar, A.; Salzer, U.; et al. Circulating multimeric immune complexes contribute to immunopathology in COVID-19. *Nat. Commun.* **2022**, *13*, 5654. [\[CrossRef\]](#)
150. Kolb, P.; Giese, S.; Voll, R.E.; Hengel, H.; Falcone, V. Immune complexes as culprits of immunopathology in severe COVID-19. *Med. Microbiol. Immunol.* **2022**, *212*, 185–191. [\[CrossRef\]](#)
151. Esteve-Sole, A.; Anton, J.; Pino-Ramirez, R.M.; Sanchez-Manubens, J.; Fumadó, V.; Fortuny, C.; Rios-Barnes, M.; Sanchez-de-Toledo, J.; Girona-Alarcón, M.; Mosquera, J.M.; et al. Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease. *J. Clin. Investig.* **2021**, *131*, e144554. [\[CrossRef\]](#) [\[PubMed\]](#)
152. Holm, S.; Kared, H.; Michelsen, A.E.; Kong, X.Y.; Dahl, T.B.; Schultz, N.H.; Nyman, T.A.; Fladeby, C.; Seljeflot, I.; Ueland, T.; et al. Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia. *Eur. Heart J.* **2021**, *42*, 4064–4072. [\[CrossRef\]](#) [\[PubMed\]](#)
153. Root-Bernstein, R. How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy. *Anti-Cancer Agents Med. Chem.* **2015**, *15*, 1242–1259. [\[CrossRef\]](#)
154. Root-Bernstein, R. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions. *Int. J. Mol. Sci.* **2021**, *22*, 2108. [\[CrossRef\]](#) [\[PubMed\]](#)
155. Root-Bernstein, R. From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis, and Multisystem Inflammatory Syndrome in Children. *Int. J. Mol. Sci.* **2023**, *24*, 3001. [\[CrossRef\]](#) [\[PubMed\]](#)
156. Root-Bernstein, R.; Churchill, E.; Oliverio, S. T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens. *Int. J. Mol. Sci.* **2023**, *24*, 1335. [\[CrossRef\]](#)
157. Westall, F.C.; Root-Bernstein, R. Cause and prevention of postinfectious and postvaccinal neuropathies in light of a new theory of autoimmunity. *Lancet* **1986**, *2*, 251–252. [\[CrossRef\]](#)
158. Root-Bernstein, R.S. Multiple-antigen-mediated autoimmunity (MAMA) in AIDS: A possible model for postinfectious autoimmune complications. *Res. Immunol.* **1990**, *141*, 321–339. [\[CrossRef\]](#)
159. Root-Bernstein, R.; Couturier, J. Antigenic complementarity in the origins of autoimmunity: A general theory illustrated with a case study of idiopathic thrombocytopenia purpura. *Clin. Dev. Immunol.* **2006**, *13*, 49–65. [\[CrossRef\]](#)

160. Root-Bernstein, R. Antigenic complementarity in the induction of autoimmunity: A general theory and review. *Autoimmun. Rev.* **2007**, *6*, 272–277. [\[CrossRef\]](#)
161. Pendergraft, W.F., 3rd; Pressler, B.M.; Jennette, J.C.; Falk, R.J.; Preston, G.A. Autoantigen complementarity: A new theory implicating complementary proteins as initiators of autoimmune disease. *J. Mol. Med.* **2005**, *83*, 12–25. [\[CrossRef\]](#) [\[PubMed\]](#)
162. Pendergraft, W.F., 3rd; Badhwar, A.K.; Preston, G.A. Autoantigen complementarity and its contributions to hallmarks of autoimmune disease. *J. Theor. Biol.* **2015**, *375*, 88–94. [\[CrossRef\]](#)
163. Bautz, D.J.; Preston, G.A.; Lionaki, S.; Hewins, P.; Wolberg, A.S.; Yang, J.J.; Hogan, S.L.; Chin, H.; Moll, S.; Jennette, J.C.; et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. *J. Am. Soc. Nephrol. JASN* **2008**, *19*, 2421–2429. [\[CrossRef\]](#) [\[PubMed\]](#)
164. Yang, J.; Bautz, D.J.; Lionaki, S.; Hogan, S.L.; Chin, H.; Tisch, R.M.; Schmitz, J.L.; Pressler, B.M.; Jennette, J.C.; Falk, R.J.; et al. ANCA patients have T cells responsive to complementary PR-3 antigen. *Kidney Int.* **2008**, *74*, 1159–1169. [\[CrossRef\]](#) [\[PubMed\]](#)
165. Hewins, P.; Belmonte, F.; Charles Jennette, J.; Falk, R.J.; Preston, G.A. Longitudinal studies of patients with ANCA vasculitis demonstrate concurrent reactivity to complementary PR3 protein segments cPR3m and cPR3C and with no reactivity to cPR3N. *Autoimmunity* **2011**, *44*, 98–106. [\[CrossRef\]](#)
166. Reynolds, J.; Preston, G.A.; Pressler, B.M.; Hewins, P.; Brown, M.; Roth, A.; Alderman, E.; Bunch, D.; Jennette, J.C.; Cook, H.T.; et al. Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by ‘autoantigen complementarity’. *J. Autoimmun.* **2015**, *59*, 8–18. [\[CrossRef\]](#)
167. Root-Bernstein, R. Age and location in severity of COVID-19 pathology: Do lactoferrin and pneumococcal vaccination explain low infant mortality and regional differences? *BioEssays* **2020**, *42*, e2000076. [\[CrossRef\]](#)
168. Root-Bernstein, R. Pneumococcal and influenza vaccination rates and pneumococcal invasive disease rates set geographical and ethnic population susceptibility to serious COVID-19 cases and deaths. *Vaccines* **2021**, *9*, 474. [\[CrossRef\]](#)
169. Root-Bernstein, R. Possible cross-reactivity between SARS-CoV-2 proteins; CRM197 and proteins in pneumococcal vaccines may protect against symptomatic SARS-CoV-2 disease and death. *Vaccines* **2020**, *8*, 559. [\[CrossRef\]](#)
170. Nunes, M.C.; Cutland, C.L.; Klugman, K.P.; Madhi, S.A. Pneumococcal conjugate vaccine protection against coronavirus-associated pneumonia hospitalization in children living with and without HIV. *mBio* **2021**, *12*, 10–1128. [\[CrossRef\]](#)
171. Jehi, L.; Ji, X.; Milinovich, A.; Erzurum, S.; Rubin, B.P.; Gordon, S.; Young, J.B.; Kattan, M.W. Individualizing risk prediction for positive coronavirus disease 2019 testing. *Chest* **2020**, *158*, 1364–1375. [\[CrossRef\]](#)
172. Pawlowski, C.; Puranik, A.; Bandi, H.; Venkatakrishnan, A.J.; Agarwal, V.; Kennedy, R.; O’Horo, J.C.; Gores, G.J.; Williams, A.W.; Halamka, J.; et al. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. *Sci. Rep.* **2021**, *11*, 4741. [\[CrossRef\]](#)
173. Noale, M.; Trevisan, C.; Maggi, S.; Incalzi, R.A.; Pedone, C.; Di Bari, M.; Adorni, F.; Jesuthasan, N.; Sojic, A.; Galli, M.; et al. the association between influenza and pneumococcal vaccinations and SARS-CoV-2 infection: Data from the EPICoVID19 web-based survey. *Vaccines* **2020**, *8*, 471. [\[CrossRef\]](#)
174. Lewnard, A.J.; Bruxvoort, K.J.; Fischer, H.; Hong, V.X.; Grant, L.R.; Jódar, L.; Gessner, B.D.; Tartof, S.Y. Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between *Streptococcus pneumoniae* and SARS-CoV-2 in the respiratory tract. *J. Infect. Dis.* **2021**, *128*, 1710–1720. [\[CrossRef\]](#)
175. Thindwa, D.; Garcia Quesada, M.; Liu, Y.; Bennett, J.; Cohen, C.; Knoll, M.D.; von Gottberg, A.; Hayford, K.; Flasche, S. Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. *Vaccine* **2020**, *38*, 5398–5401. [\[CrossRef\]](#) [\[PubMed\]](#)
176. Amin-Chowdhury, Z.; Aiano, F.; Mensah, A.; Sheppard, C.L.; Litt, D.; Fry, N.K.; Andrews, N.; Ramsay, M.E.; Ladhani, S.N. Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Invasive Pneumococcal Disease and Risk of Pneumococcal coinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Prospective national cohort study, England. *Clin. Infect. Dis.* **2021**, *72*, e65–e75. [\[CrossRef\]](#) [\[PubMed\]](#)
177. Dennert, R.; Crijns, H.J.; Heymans, S. Acute viral myocarditis. *Eur. Heart J.* **2008**, *29*, 2073–2082. [\[CrossRef\]](#)
178. Lawson, C.M. Evidence for mimicry by viral antigens in animal models of autoimmune disease including myocarditis. *Cell. Mol. Life Sci. CMLS* **2000**, *57*, 552–560. [\[CrossRef\]](#) [\[PubMed\]](#)
179. Reddy, J.; Massilamany, C.; Buskiewicz, I.; Huber, S.A. Autoimmunity in viral myocarditis. *Curr. Opin. Rheumatol.* **2013**, *25*, 502–508. [\[CrossRef\]](#)
180. Ashrafi, R.; McKay, E.; Ebdon, L.; Jones, J.; Davis, G.K.; Burgess, M.I. Endocarditis in a large district general hospital: A study of the microbiological spectrum between 2000 and 2011. *Exp. Clin. Cardiol.* **2012**, *17*, 175–178.
181. Kogut, E.P.; Levashova, N.V.; Bondarenko, A.P.; Zherdeva, A.I.; Shuvalova, I.A. Eksperimental’noe izuchenie koksakii-streptokokkovoi infektsii [Experimental study of Cocksackie-streptococcal infection]. *Vopr. Virusol.* **1978**, *37*, 690–695.
182. Suresh, L.; Chandrasekar, S.; Rao, R.S.; Ravi, V.; Badrinath, S. Cocksackie virus and rheumatic fever. A correlative study. *J. Assoc. Physicians India* **1989**, *37*, 582–585. [\[PubMed\]](#)
183. Kalpana, S.R.; Saikant, R.; Nanjappa, M.C.; Mahadevan, A.; Jayshree, R.S. The prevalence of enteroviral RNA and protein in mitral valves of chronic rheumatic heart disease. *J. Infect. Dev. Ctries.* **2021**, *15*, 566–572. [\[CrossRef\]](#) [\[PubMed\]](#)
184. Muir, P. Enterovirus infection of the heart—a causal or contributory factor in chronic rheumatic heart disease? *Eur. Heart J.* **2002**, *23*, 517–520. [\[CrossRef\]](#)

185. Tay, L.; Yin-Murphy, M.; Chua, P.H.; Koh, L.H. Prevalence of coxsackievirus B antibody in patients with suspected rheumatic fever and rheumatic heart disease. *Singap. Med. J.* **1983**, *24*, 37–40.
186. Burch, G.E.; Giles, T.D. The role of viruses in the production of heart disease. *Am. J. Cardiol.* **1972**, *29*, 231–240. [[CrossRef](#)]
187. Kato, N.; Fujii, Y.; Agata, N.; Kido, N.; Ohta, M.; Naito, S.; Yokochi, T. Experimental murine model for autoimmune myocarditis using *Klebsiella pneumoniae* O3 lipopolysaccharide as a potent immunological adjuvant. *Autoimmunity* **1993**, *14*, 231–236. [[CrossRef](#)]
188. Granholm, A.; Munch, M.W.; Andersen-Ranberg, N.; Myatra, S.N.; Vijayaraghavan, B.K.T.; Venkatesh, B.; Jha, V.; Rubenson, R.W.; Jakob, S.M.; Cioccarl, L.; et al. Heterogenous treatment effects of dexamethasone 12 mg vs. 6 mg in patients with COVID-19 and severe hypoxaemia—post hoc exploratory analyses of the COVID STEROID 2 trial. *Acta Anaesthesiol. Scand.* **2022**, *67*, 195–205. [[CrossRef](#)]
189. Broering, R.; Montag, M.; Jiang, M.; Lu, M.; Sowa, J.P.; Kleinehr, K.; Gerken, G.; Schlaak, J.F. Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state. *Int. Immunol.* **2011**, *23*, 537–544. [[CrossRef](#)]
190. Sohlenkamp, C.; Geiger, O. Bacterial membrane lipids: Diversity in structures and pathways. *FEMS Microbiol. Rev.* **2016**, *40*, 133–159. [[CrossRef](#)]
191. López-Lara, I.M.; Geiger, O. Bacterial lipid diversity. *Biochimica et biophysica acta. Mol. Cell Biol. Lipids* **2017**, *1862*, 1287–1299. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.